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This thesis aimed at the development of strategies that could contribute to the 
evaluation of the clinical potential of new anticancer therapies. The work was divided 
into two main sections comprising the development of a therapeutic approach to target 
cancer genetic vulnerabilities and the development of 3D tumor models incorporating 
cues from the stromal and immune microenvironments. 
In the first part of the work, we evaluated the feasibility of a therapeutic strategy based 
on gene therapy to target tumor genetic vulnerabilities. Basal-like Breast Cancer (BLBC) 
usually manifests as high grade aggressive tumors with poor prognosis. Since there are 
no validated molecular targets for this subtype, current therapeutic options are based 
on cytotoxic chemotherapy. This results in high toxicity due to side effects, and most 
patients relapse after a few years. Thus, there is a need to develop targeted therapies 
that can improve prognosis for BLBC patients. For this, in Chapter II, we generated 
small-hairpin RNA (shRNA) sequences targeting genetic vulnerabilities previously 
identified for this subtype. 
Adeno-associated viral (AAV) vectors have been increasingly used in clinical trials. These 
present low toxicity in vivo and support long-term transgene expression. Thus, AAV-
based viral vectors were chosen as the delivery agent for the generated shRNA 
sequences. Using this strategy, we were able to confirm BLBC cells´ increased 
dependency on the proteasome machinery, as previously reported. AAV-mediated 
delivery of shRNA targeting PSMA2, a proteasome machinery subunit, induced 
significant target gene knockdown, which resulted in a 2-fold apoptosis induction in 
BLBC cell lines. Moreover, intratumoral injection of the developed AAV vectors led to a 
reduction of tumor growth over time, in a mouse BLBC xenograft model. These results 
suggest that the developed strategy could be used to target cancer-intrinsic genetic 
vulnerabilities and interrogate their clinical potential. Nevertheless, the AAV serotype 
used in this work – AAV2 - presents a very broad tropism. Thus, in Chapter III, we took 
advantage of AAV´s amenability for capsid engineering to restrict its tropism towards 
BLBC. This would lower the off-target effects, as it would reduce infection of non-
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relevant tissues. For this, and since there are no known receptors specific for BLBC, we 
applied a directed evolution approach using an AAV2 random peptide library to restrict 
its tropism towards BLBC. After multiple rounds of infection on BLBC cell lines, a 15% 
enrichment was achieved for a single peptide motif. However, analysis of its 
transduction properties reveled that it was not specific for BLBC. Furthermore, it 
presented increased transduction efficiency for normal breast epithelial cells and 
human dermal fibroblasts. These findings limit its potential for BLBC targeted therapy 
and, since this was our main goal, the studies were concluded. 
In the second part of the work, we aimed at the development of 3D heterotypic tumor 
models that could better represent the crosstalk between different players within the 
tumor microenvironment (TME) and be used to screen novel drug candidates. 
The increasing understanding that TME cues play a decisive role in the outcome of 
cancer drug response urges its integration in preclinical tumor models. Several 
anticancer therapies require the presence of an engaged immune system to enhance 
their efficacy. These include untargeted approaches, namely chemo- and radiotherapy, 
as well as targeted molecular approaches aiming at inducing tumor cell death. 
Therefore, in Chapter IV, we developed a 3D co-culture model that incorporated three 
cellular compartments: tumor - non-small cell lung cancer (NSCLC) spheroids, stromal – 
cancer-associated fibroblasts (CAF), and immune – monocytes. The tumoral 
compartment was composed of proliferative cells and presented phenotypic features 
characteristic of aggressive stages of NSCLC, such as cells positive for vimentin and 
cadherin 2. The monocytes in culture differentiated into macrophages which presented 
phenotypic characteristics of M2-like polarization, such as expression of CD163 and 
MRC1. These markers have been described for tumor-associated macrophages (TAM), 
also present in human NSCLC tumors. Moreover, the cytokine secretory profile 
evidenced an immunosuppressive TME, with accumulation of cytokines such as IL4, 
IL10, IL13, CCL22, CCL24 and CXCL1. Specific increase in matrix metalloproteases MMP1 
and 9 and extensive accumulation of extracellular matrix (ECM) components, such as 
collagen I and IV and fibronectin, suggested progression into an aggressive and invasive 
tumoral state. The spatial distribution of the different cells was altered along culture 
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time, with extravasation of tumor cells into the surrounding stroma, accompanied by 
an infiltration of the macrophages into the tumoral mass, as evidenced by light-sheet 
fluorescence microscopy and histology. Although probably supported by the MMP 
expression and ECM accumulation, this indicated that the alginate microcapsules were 
amenable to cell migration, enabling cell-cell contacts and supporting myeloid cell 
infiltration, thus mimicking several aspects of the aggressive and immunosuppressive 
TME of NSCLC.  
Finally, this model allowed the interrogation of both tumor and myeloid targeting drugs, 
and depiction of their effect on tumor cell viability. Upon challenge with two standard-
of-care chemotherapeutics – paclitaxel and cisplatin – we were able to identify a lower 
susceptibility of the tumor compartment to paclitaxel, when in triple co-culture with 
CAF and TAM. This suggests that the TME may be responsible for acquired resistance to 
taxane chemotherapies. Moreover, upon challenge with a macrophage receptor 
(CSF1R) inhibitor, the macrophage phenotype was modulated, resulting in a decrease 
of the M2-like macrophages in culture and concomitant increase in the expression of 
M1-like macrophage markers, namely CCR7. Thus, the model developed constitutes a 
novel tool to study macrophage plasticity and repolarization in response to 
chemotherapeutic and immunomodulatory drugs. Moreover, it is compatible with 
continuous monitoring and high-throughput platforms, facilitating its integration in 
drug screening and disease modeling studies.  
Finally, we hope that the experimental approach and data gathered during this thesis, 
that could potentially also be applied to different cancer pathologies, can contribute to 
the identification of novel actionable molecular targets and to the dissection of the 






Esta tese de doutoramento teve como objectivo o desenvolvimento de estratégias in 
vitro que pudessem contribuir para avaliar o potencial clínico de novas terapias contra 
o cancro. O trabalho foi dividido em duas partes: A) o desenvolvimento de uma 
abordagem terapêutica que permitisse explorar vulnerabilidades genéticas tumorais e 
B) o desenvolvimento de modelos tumorais 3D que incorporassem componentes do 
estroma e sistema imunitário presentes no microambiente tumoral. 
Na primeira parte deste trabalho (A), procedeu-se à avaliação do potencial de uma 
estratégia terapêutica baseada em terapia génica, direccionada a vulnerabilidades 
genéticas tumorais. O cancro de mama do subtipo basal (BLBC) é um dos subtipos mais 
agressivos e com pior prognóstico, uma vez que não pode beneficiar das terapias 
direccionadas existentes contra os restantes subtipos de cancro de mama por não 
expressar os respectivos receptores membranares. BLBC tem então como única opção 
terapêutica a quimioterapia citotóxica. Embora apresente elevada taxa de resposta à 
terapia, esta resulta em consideráveis efeitos secundários e a maioria dos doentes sofre 
de recaída passado poucos anos. Assim, torna-se necessário o desenvolvimento de 
terapias direccionadas que possam melhorar o prognóstico de doentes com BLBC. Para 
isso, no Capítulo II, tomámos partido de vulnerabilidades genéticas que tinham sido 
previamente identificadas para este subtipo por Petrocca et al. (2013). Assim, foram 
geradas sequências de small-hairpin RNA (shRNA) que pudessem mediar a diminuição 
da expressão dos genes alvos. 
Os biofármacos derivados de vírus recombinantes são frequentemente utilizados como 
vectores de terapia génica. Os vectores baseados em vírus adeno-associados (AAV) 
ocupam um segmento importante deste mercado, sendo hoje em dia o vector viral mais 
utilizado em ensaios clínicos. Estes apresentam um perfil clínico seguro e eficaz, assim 
como uma capacidade de mediar expressão prolongada do transgene. Como tal, 
vectores virais baseados em AAV foram escolhidos como veículo para a terapia genética 
desenvolvida. Procedeu-se à produção e purificação de AAV expressando como 
transgene as sequências de shRNA previamente identificadas. Usando esta estratégia, 
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foi possível confirmar a dependência que BLBC apresenta para com o proteassoma. 
Knockdown de uma das subunidades do proteassoma - PSMA2 - induziu morte celular 
por apoptose em células de BLBC. Mais, injecções intratumorais dos AAV a expressar 
sequências de shRNA contra PSMA2 resultaram na diminuição do crescimento tumoral 
ao longo do tempo, quando comparado com ratinhos injectados com PBS ou com um 
vector controlo. Estes resultados sugerem que esta estratégia poderá apresentar 
potencial para ser usada como terapia direccionada para alvos moleculares com 
potencial terapêutico. No entanto, o serotipo de AAV utilizado – AAV2 – apresenta um 
tropismo que abrange múltiplos tecidos. Visto isto, no Capítulo III procedemos à 
alteração proteica da cápside com o objectivo de restringir o tropismo deste vector para 
BLBC. Assim, seria possível reduzir os efeitos secundários resultantes da terapia, 
mediados pela infecção inespecífica de células que não as alvo. Para isso, usámos uma 
biblioteca de péptidos apresentada em cápsides de AAV para, numa abordagem 
baseada em evolução dirigida, isolar uma variante com tropismo específico para este 
subtipo de cancro de mama. No entanto, após múltiplos rounds de infecções da referida 
biblioteca em linhas celulares derivadas de BLBC, foi apenas possível enriquecer a 
biblioteca numa única sequência peptídica, que representava 15% da preparação final. 
Após análise do tropismo desta variante em linhas celulares derivadas de vários tecidos, 
verificou-se que a sua capacidade de transdução não era restricta a células de BLBC. 
Além disso, a eficiência de transdução para células primárias derivadas do epitélio 
mamário e para fibroblastos humanos apresentava-se aumentada, diminuindo assim o 
potencial desta variante para ser usada com agente de terapia génica para este subtipo 
tumoral.  
A segunda parte do trabalho (B) teve como objectivo o desenvolvimento de modelos 
celulares heterotípicos com possam ser usados como modelo de doença e para a 
avaliação de novas terapêuticas contra o cancro. 
O microambiente tumoral (TME) influencia directamente a resposta a drogas por parte 
do tumor. A incorporação dos elementos presentes neste TME em modelos celulares 
pré-clínicos poderá permitir uma melhor avaliação da sua eficácia e modo de acção. 
Assim, no Capítulo IV, desenvolvemos um modelo celular de co-cultura de três tipos 
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celulares presentes no TME: esferoides tumorais derivados de cancro do pulmão de 
não-pequenas células (NSCLC), fibroblastos associados a tumor (CAF) e monócitos. O 
compartimento tumoral neste modelo apresentava células proliferativas e 
características fenotípicas de estágios tardios de NSCLC, nomeadamente a presença de 
células positivas para vimentina e n-caderina.  Por outro lado, os monócitos em cultura 
diferenciaram para macrófagos com expressão de CD163 e MRC1. Estes marcadores 
membranares sugerem um estado de polarização M2, característicos dos macrófagos 
associados a tumor (TAM) presentes neste subtipo tumoral. Além disso, o perfil de 
secreção de citocinas nas culturas triplas apresentava uma acumulação de citocinas 
características do TME imunossupressor encontrado neste tipo tumoral, 
nomeadamente IL4, IL10, IL13, CCL22, CCL24 e CXCL1. Acumulação de componentes da 
matrix extracelular nas cápsulas de alginato suportou uma remodelação extensa dos 
compartimentos celulares durante a cultura. Foi possível observar infiltração de 
macrófagos na massa tumoral, algo que é visível em amostras derivadas de pacientes 
de NSCLC. 
Como prova de conceito este modelo foi sujeito a drogas quimioterapêuticas usadas na 
clínica. Assim, foi possível diferenciar o efeito na viabilidade tumoral destas drogas na 
presença ou ausência dos restantes componentes do TME. O compartimento tumoral 
apresentou uma susceptibilidade reduzida a paclitaxel quando em co-cultura com CAF 
e TAM. Isto poderá sugerir que o TME tem um efeito na aquisição de resistência a 
quimioterapia mediada por taxanos, e realça a importância da incorporação desta 
componente nos modelos tumorais pré-clínicos. Por fim, o modelo foi sujeito a um 
composto imunomodulatório que tem como alvo os macrófagos. O tratamento com um 
inibidor do receptor de macrófagos CSF1R resultou na diminuição da percentagem de 
células positivas para os marcadores de macrófagos M2 – CD163 e MRC1 – e aumento 
da expressão de um marcador de macrófagos M1 – CCR7. Este efeito tinha sido 
previamente descrito para o inibidor utilizado, comprovando assim o potencial do 
modelo desenvolvido para a avaliação do efeito imunomodulatório na população 
mieloide de novos compostos com potencial terapêutico. 
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Por fim, esperamos que a abordagem experimental e dados recolhidos ao longo deste 
trabalho, que podem potencialmente ser aplicados a diferentes patologias oncológicas, 
possam contribuir para a identificação de novos alvos moleculares terapêuticos e para 
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Cancer progression has been compared to the development of multicellular organisms 
where mechanisms controlling cell division, cell-fate determination and tissue 
organization are deregulated[1]. Understanding which physiological processes are 
being co-opted by tumors to thrive in harsh physicochemical conditions and avoid cell 
death, acquire unrestricted growth capacity and the propensity to invade adjacent 
tissues and disseminate throughout the host, will be crucial for rational design of 
efficacious therapies. These properties emerge in different tumor types through distinct 
mechanisms and are enabled by both tumor cell intrinsic and extrinsic properties (Fig. 
1.1)[2]. 
 
Figure 1.1: Tumor cell intrinsic and extrinsic properties influencing the different 
hallmarks of tumor biology. Adapted from Hanahan et al., Cancer Cell (2012)[2]. 
Chapter I 
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2. INTRINSIC CHARACTERISTICS – THE QUEST FOR CANCER-SPECIFIC 
VULNERABILITIES 
A fundamental feature of cancer is genomic instability. The progression from normal 
into malignant cells accompanies an accumulation of mutations or altered expression in 
specific genes, that confers them tumorigenic potential. These genes, termed either 
tumor suppressors or oncogenic drivers, generate tissue or cancer subtype-specific 
genetic vulnerabilities, and constitute prime candidates for targeted therapies. The 
discovery and exploitation of such targets over the years has drastically improved 
cancer treatment. 
2.1 Chronic Proliferation and Survival 
Normal tissues depend on controlled growth signaling and cell cycle to maintain 
homeostasis, which is disrupted in cancer. Oncogenic signaling through receptor 
tyrosine kinases (RTK), either by upregulation of receptor expression or by aberrant 
activation of the downstream signaling pathways in the absence of growth factors, 
drives tumor initiation and progression across several solid tumors[3]. RTK constitute 
cell surface receptors for many growth factors that regulate several biological processes 
including the maintenance of chronic proliferation in tumor cells (Fig. 1.2)[4]. In fact, 
the first reports linking a genetic alteration to the development of cancer involved the 
erb-b2 receptor tyrosine kinase 2 (ERBB2) gene[5]. This gene, commonly referred to as 
HER2, was shown to be amplified in up to 20% of invasive breast cancers, and it 
correlated with decreased overall survival and reduced time of relapse[6]. This 
potentiated the development of the first therapies targeting cancer molecular 
aberrations, namely monoclonal antibodies (trastuzumab and pertuzumab), tyrosine 
kinase inhibitors (lapatinib), and antibody–drug conjugates, which improved the 
outcome for HER2+ breast cancer patients[7]. 
ERBB2 belongs to the ERBB family of RTK, which entails another prototypical example - 
epidermal growth factor receptor (EGFR). Activating mutations in this receptor can be 
found in high proportion in different tumor types, including glioblastoma, 




Figure 1.2: Main downstream pathways of ERBB2 and EGFR. A) Model depicting the action of 
small-molecule inhibitor or antibody and consequent downstream signaling suppression. B) 
Model depicting an ERBB2-amplified or EGFR mutant cancer, where the maintenance of 
downstream signaling in the presence of inhibitors is achieved by i) activation of additional RTK 
or ii) constitutive mutational activation of downstream signaling. Adapted from Arteaga et al., 
Cancer Cell (2014)[3]. 
medulloblastoma, breast, head and neck, ovarian, lung and prostate[8]. In transgenic 
mouse models, mutant EGFR expression induces lung adenocarcinomas, and inhibition 
of EGFR signaling by small molecule inhibitors, such as erlotinib, or monoclonal 
antibodies, such as cetuximab, leads to tumor regression[9], thus confirming both its 
role as an oncogenic driver and as an oncogenic addiction that can be targeted for 
clinical benefit. The development of EGFR blockers has drastically improved the 
outcome of patients with tumors bearing activating mutations of this receptor, 
especially in non-small cell lung cancer (NSCLC) metastatic setting[10]. Still, single agent 
strategies fall short in clinical trials; constant exposure to RTK inhibitors often induces 
resistance through secondary mutations in downstream pathways or through 
compensatory activation of alternative RTK, such as MET proto-oncogene, receptor 
tyrosine kinase (MET) or insulin-like growth factor 1 receptor (IGF1R), maintaining 
overall survival signaling (Fig. 1.2 – B)[3]. Large-scale high-throughput approaches for 
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mapping cellular signaling networks showed that cancer cells also activate several RTK 
simultaneously[11]. Such RTK co-activation influences tumor response to targeted 
therapies[12] and is a frequent mechanism of acquired resistance in tumor cells[13,14]. 
Downstream mediators of these receptors include mitogen-activated protein kinase 
(MAPK), phosphoinositide 3-kinase/AKT Serine-Threonine Kinase (PI3K/AKT), 
mechanistic target of rapamycin kinase (MTOR) and Janus kinase/signal transducers and 
activators of transcription (JAK/STAT) pathways, as well as, SRC proto-oncogene, non-
receptor tyrosine kinase (SRC)[3]. DNA sequencing analysis has shown that somatic 
mutations in protein regulators of these pathways constitute common oncogenic 
drivers and result in constitutive signaling that is usually attributed to activated growth 
factor receptors[2]. This confers the necessary plasticity for tumor cells to retain 
proliferative signaling even when one of these elements is disrupted[11]. To overcome 
these mechanisms, combinatorial strategies have been developed and often attain 
higher decrease in tumor cell viability than any of the monotherapies tested[12,15]. 
2.2 Cell Death Evasion 
Hyperproliferation and overexpression of oncogenes often results in DNA damage that 
is a potent trigger of apoptosis[2]. However, malignant transformation often entails 
deregulation of apoptotic signaling or activation of antiapoptotic systems, rendering 
tumor cells resistant to apoptosis stimuli, which further supports uncontrolled 
proliferation and survival signaling[16]. This escape from normal control of cell death 
networks aids proliferative cells and contributes to survival, leading to the development 
of higher grade malignancy, and contributing directly to therapeutic resistance and 
disease recurrence[16]. 
Various mechanisms culminate in apoptosis evasion; key examples include mutations in 
regulatory proteins such as tumor protein p53 (TP53) and RB transcriptional corepressor 
1 (RB1)[2]. The former is a tumor suppressor gene that was identified as the most often 
mutated in cancer and leads to detrimental phenotypes across several cancer 
types[17,18]. It acts as a stress detector with a prominent role in determining how the 
cell responds to DNA damage, nutrient deprivation and hypoxia, by either promoting 
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cell survival or arresting cell proliferation and inducing apoptosis[19]. Alternative 
mechanisms include upregulation of survival signaling and of antiapoptotic regulators, 
such as members of the BCL2 family[2]. The latter regulate the intrinsic apoptosis 
pathway (Fig. 1.3)[20]. Overexpression of these proteins confers chemotherapy 
resistance to pancreatic, ovarian, lymphoma, multiple myeloma, lung adenocarcinoma, 
prostate adenocarcinoma, among others[16]. 
 
Figure 1.3: Different categories of the BCL2 family. In red: antiapoptotic proteins; in yellow: 
proapoptotic multidomain that permeabilizes the outer mitochondrial membrane (intrinsic 
apoptosis pathway); in blue: BH3-only proteins agonists for the proapoptotic multidomain and 
antagonists of antiapoptotic BCL2 members; and in brown: BH3-containing proapoptotic 
members that serve as antagonists of antiapoptotic BCL2 members. Also illustrated is TP53’s role 
in regulating proapoptotic stimuli after stress, such as chemotherapeutic challenge. Finally, the 
actions of venetoclax, an BCL2 antagonist, is also depicted. Adapted from Croce et al., Cancer 
Res (2016)[21]. 
Several small molecule inhibitors have been developed that target mediators of this 
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pathway and, recently, FDA approval of venetoclax, a BCL2, apoptosis regulator (BCL2) 
inhibitor, constituted the first apoptosis-targeting drug available for cancer patients 
(Fig. 1.3)[21]. Possible resistance mechanisms to BCL2 inhibition include the 
upregulation of MCL1, BCL2 family apoptosis regulator (MCL1) and BCL2 like 1 (BCL2L2) 
genes (Fig. 1.3)[22]. Functional studies into MCL1 function, have shown that it blocks 
apoptosis induced by many chemo- or radiotherapeutic stimuli[16]. MCL1 is 
overexpressed in many different tumors[23] and, contrary to other BCL2 family 
proteins, has a very short half-life[24] due to proteasome degradation[25]. Therefore, 
targeting MCL1 expression can be a promising approach[26–28]. Although several 
reports studied the effect of antisense oligonucleotide (ASO) therapy targeting MCL1, 
these have yet to be successfully translated into the clinic, possibly due to the low 
stability of ASO in circulation[29]. 
The proteasome machinery has also been implicated in evading apoptosis, since some 
of its substrates are protein regulators of cell survival and apoptotic pathways[30]. A 
compromised proteasome regulation can induce tumorigenesis by altering the turnover 
of key oncogene or tumor suppressor gene protein products[31]. In fact, while 
functional in healthy tissue, bortezomib, a 20S proteasome inhibitor, is only toxic for 
cancer cells, indicating a selective dependency of cancer cells[31]. The proteasome 
machinery controls TP53 protein levels and activity[32,33], as well as protein regulators 
of the BCL2 family, including BCL2 interacting killer (BIK), phorbol-12-myristate-13-
acetate-induced protein 1 (PMAIP1, also known as NOXA) and BCL2 like 11 (BCL2L11, 
also known as BIM) proteins (Fig. 1.3)[34]. Proteasome can also regulate cell cycle 
progression by controlling the turnover of cyclins and cyclin-dependent kinase 
inhibitors[35], as well as of transcription factors implicated in cell survival pathways, 
such as nuclear factor kappa B (NFKB)[36]. 
Targeted inhibition of proteasome pathway mediators may switch the balance towards 
tumor cell death by inducing the accumulation of proapoptotic proteins[16]. The 
development of inhibitors of the proteasome machinery has led to significant 
improvements in cancer care, mainly in hematological malignancies[31]. On the other 
hand, for solid cancers, the translation of the promising preclinical results has been 
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challenging. Primary and acquired resistance does occur, and it has been linked to 
mutations or overexpression of proteasomal subunits, among others[31]. Thus, more 
predictive preclinical models are needed, along with further investigation into the 
mechanisms of resistance in order to optimize combinatorial regimens and broaden the 
applicability and efficacy of proteasome inhibitor therapy[31]. 
2.3 Reprograming of cell energy metabolism 
Oncogenic growth signaling needs support from cell-autonomous nutrient uptake and 
from metabolic regulation to accommodate proliferation[37]. Therefore, cancer cells 
undergo metabolic reprogramming in order to fuel the biological processes behind 
biomass formation, tumor growth and energy generation, and to survive the stresses 
associated, namely oxidative stress[38]. While glucose metabolism in normal 
differentiated cells is mainly dependent on oxidative phosphorylation, cancer cells 
undergo a metabolic switch, termed Warburg effect, thus relying mostly on aerobic 
glycolysis[37]. Although it generates less ATP per glucose molecule, it allows fast ATP 
production even at low oxygen tension, which occurs at later stages of tumor 
development. Plus, ATP requirements for proliferation do not differ significantly from 
normal homeostasis[37] Interestingly, most signaling pathways driving cell growth are 
involved in cell metabolism regulation[37]. Glucose uptake inhibition leads to cell death 
in a manner similar to what happens when growth factor signaling is inhibited[37]. 
Moreover, the excess nutrient uptake, consequence of increased cell growth receptor 
signaling, if not converted into aerobic glycolysis would greatly increase reactive oxygen 
species production, a byproduct of oxidative phosphorylation[37]. 
This metabolic shift is not exclusive of malignancy phenotypes; thus, it may result from 
reversion into a more embryonic state or an independent ability to undergo metabolic 
reprogramming[37]. Some metabolic activities are prompted by oncogenic drivers and 
may provide tumor dependencies to be exploited in the clinic[38]. For example, somatic 
mutations in genes encoding isocitrate dehydrogenase (NADP(+)) 1/2 (IDH1, IDH2) are 
abundant in a large variety of tumors and have been proposed to lead epigenetic 
changes that promote tumorigenesis through inhibition of normal cell 
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differentiation[39]. However, inhibition of 2-hydroxyglutarate, an oncometabolite of 
IDH-mutant tumors, did not decrease tumor growth, highlighting the importance of 
alternate and cooperating metabolic pathways[40]. In fact, the standard strategy of 
conducting in vitro screens followed by in vivo validation, which provided important 
therapeutic targets like the ones mentioned in the former sections, has particularly low 
efficacy for metabolic targets[38]. For example, in NSCLC, cultured cells used glutamine 
as the main carbon source for the tricarboxylic acid (TCA) cycle, while tumors in vivo 
showed greater dependency on glucose carbon contribution and no differential 
contribution of glutamine to the TCA cycle between tumor and normal tissue was 
found[41]. These results highlight the importance of proper preclinical model selection, 
as culture conditions are often non physiological and selective for higher proliferating 
cell clones[41]. Additionally, metabolically heterogeneity was observed within NSCLC 
patients, emphasizing the need to take the environmental context into account when 
selecting metabolic targets[42]. Effective strategies to target cancer metabolism will 
need to be supported by a better understanding of the reciprocal interactions between 
cancer-dependent and stromal cell signals[38], as well as with the host and diet 
microbiomes[43]. To improve patient stratification and therapeutic selection, we need 
cell culture strategies that  retain tumor metabolic requirements, as well as better tools 
to assess quantitatively metabolic fluxes in co-culture contexts[38]. 
3. EXTRINSIC CHARACTERISTICS – HETEROTYPIC INTERACTIONS WITHIN THE 
TUMOR MICROENVIRONMENT 
3.1 Epithelial to Mesenchymal Transition (EMT) 
The considerable plasticity demonstrated by cancer cells allows them to transition 
between multiple and dynamic states separating epithelial and mesenchymal 
phenotypes[44]. Cells with partial EMT phenotype, which exhibit hybrid 
epithelial/mesenchymal characteristics, are involved in embryonic development and 
organ formation[45], wound healing and fibrosis in adult tissues[46], and cancer 
progression[44]. These transitioning states constitute final functional cell phenotypes; 
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therefore, it is important to contextualize EMT within the cellular process it is 
contributing to, namely invasion, survival, decreased proliferation, production of 
extracellular matrix (ECM) and resistance to therapy[44]. 
While oncogenic drivers, such as RAS and EGFR mutations, may elicit a shift towards the 
mesenchymal state (EMT), this induction is intimately connected with the signaling 
molecule network present in the tumor microenvironment (TME), which depends on 
the tissue of origin and on the network of cells that surround the tumor[44,47]. Key 
soluble factors secreted the cells comprising the TME that mediate EMT are 
transforming growth factor beta 1 (TGFB1) and interleukin (IL) 6. TGFB1 has a pleiotropic 
role as it may function both as a tumor suppressor, promoting growth arrest at early 
stages of tumorigenesis[48], or as tumor promoter, inducing EMT and cell migration and 
invasion[49]. The cues driving each behavior are not fully understood. Upon binding, 
TGFB1 signaling activates SMAD, PI3K/AKT or MAPK downstream pathways, depending 
on the cell type, and promotes EMT by upregulation of EMT-associated transcription 
factors (EMT-TF)[49] and downregulation of cadherin 1 (CDH1) and tight junction 
protein 1 (TJP1)[50,51]. TGFB1 has also been linked to other cellular processes triggered 
by EMT, such as the acquisition of stem-like characteristics by cancer cells[52]. IL6, on 
the other hand, is linked to chronic inflammation and has been shown to induce EMT 
by eliciting STAT3 phosphorylation in NSCLC and breast cancer (BC)[53,54], and by 
promoting cancer stem cell self-renewal[55]. Nevertheless, other TME growth factors 
and cytokines, as well as oxidative stress, hypoxia, morphogenic signaling (e.g., NOTCH 
and WNT) can induce expression of EMT-TF[44]. There is considerable crosstalk 
between the different pathways and cellular players, and no individual stimulation 
appears to be sufficient to induce the molecular and phenotypic changes associated 
with EMT[47]. 
EMT transitioning states result of a balance between several transcriptional drivers and 
suppressors, whose expression is regulated at different levels including epigenetic 
modifications, transcriptional control, alternative splicing, protein stability and 
subcellular localization[44]. The major EMT-TF are: the snail family transcriptional 
repressor 1/2 (SNAI1/2) and the zinc finger E-box binding homeobox 1 (ZEB1/2), strong 
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epithelial suppressors; and twist family bHLH transcription factor 1 (TWIST1), a 
mesenchymal inducer[44]. All these induce EMT through transcriptional suppression of 
various epithelial markers including CDH1, claudins and occludins, and upregulation of 
mesenchymal markers, such as vimentin and fibronectin 1[44]. These result is a change 
in cell polarity, matrix metalloprotease (MMP) expression and cytoskeleton 
arrangement, giving cells the ability to detach and invade surrounding tissue and, 
ultimately, enter the bloodstream and migrate in response to environmental 
stimuli[44]. 
Other functional implications of EMT include inhibition of cellular senescence and 
reduced susceptibility to apoptosis by inducing MAPK and PI3K/AKT survival pathways 
and BCL2 members[56]. Acquired chemoresistance is common in cells that underwent 
EMT, a feature that is independent on their metastatic potential[57,58]. Finally, the 
expression of EMT-TF can activate the expression of pro-inflammatory and 
immunosuppressive cytokines, thus modulating the immune infiltrate towards tumor 
promotion[59]. 
Cancer therapies should be designed in combinations that account for this shift in 
phenotype and network rewiring, thus acting preemptively[44]. However, the 
applicability of EMT for cancer treatment has been limited by the intrinsic heterogeneity 
of the phenomena in tumor cells in vivo, as well as of the TME[44]. The proportion and 
distribution of the different phenotypes also depends on the intrinsic molecular 
heterogeneity and cell of origin of tumors; for example, basal-like breast cancer (BLBC) 
subtype tends to have a higher proportion of cancer stem cell (CSC)-like cells with a 
more mesenchymal phenotype than BC from HER2 positive and luminal subtypes[44]. 
Additionally, cancers arising from mesoderm (sarcomas and melanoma) tend to display 
higher EMT score than solid tumors of epithelial origin[44]. Therefore, EMT’s clinical 
significance should be evaluated in parallel with intrinsic molecular subtypes[44]. Thus, 
while reversing EMT may be a suitable strategy for fibrosis, the inherent complexity of 
the process in cancer progression suggests that it might be more effective to target and 
destroy cells that have undergone EMT[44]. Still, the lack of adequate preclinical models 
and advanced characterization techniques to visualize EMT in vivo is hampering 
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therapeutic development[44]. A pressing issue is the deciphering the full range of 
transitioning EMT states, its function in tumor progression, and their intracellular 
regulation[44]. 
3.2 Invasion and metastasis 
Metastasis is a multistep process that involves invasion of adjacent tissue, intravasation 
into the blood stream, extravasation at a distant organ and colonization of the 
metastatic site, where it may lay dormant for years or progress into clinical metastatic 
disease (Fig. 1.4)[60]. Metastasis is still the main cause of cancer-related deaths[61], 
and each step is directly linked with reciprocal interactions maintained with elements 
of the TME (Fig. 1.4)[60]. 
 
Figure 1.4: The metastatic process. Depiction of the different EMT stages cancer cells undergo 
during the metastatic cascade. The contribution of cells from the TME is also illustrated, namely 
tumor-associated macrophages (TAM) and cancer associated fibroblasts (CAF). These can be 
recruited prior and during the establishment of both primary and metastatic niches and 
contribute to the plasticity tumor cells exhibit in order to invade the surrounding tissues, survive 
within the bloodstream and colonize distant sites of metastasis. E: epithelial tumor cell; EM1 and 
EM2/3: intermediate EMT stages; M: mesenchymal tumor cell; CTC: circulating tumor cells or 
clusters. Adapted from Nieto et al., Cell (2016)[44]. 
The ability of cancer cells to undergo metastasis is often preceded by the acquisition of 
a motile phenotype. While shifting towards a mesenchymal phenotype confers cancer 
cells higher motility and invasive capacities, its functional role in metastasis is still under 
intense investigation[60]. In a spontaneous breast-to-lung metastasis mouse model, 
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downregulation of ZEB1 and ZEB2 rendered tumor cells in a permanent epithelial state 
but did not impair lung metastasis[58]. In contrast, conditional SNAI1 deletion ablated 
metastatic capability of breast cancer in vivo, while transient SNAI1 overexpression 
increased both disseminated tumor cells and lung metastasis[62]. In line with these 
results, expression of SNAI1, SNAI2 and TWIST1 genes was strongly correlated with 
metastatic breast cancer progression, in contrast with ZEB1[63]. On the other hand, in 
a pancreatic cancer mouse model, downregulation of TWIST1 and SNAI1 had no impact 
on cell invasion and metastasis[57], while downregulation of ZEB1 strongly impacted 
tumor initiation, invasion capability and metastasis formation during pancreatic cancer 
progression[64]. Therefore, there is considerable functional heterogeneity between 
EMT-TF, as well as tissue and cancer subtype specificity in their biological role. Thus, the 
functional contribution of EMT to metastasis and tumor progression needs to be 
investigated in a cancer type dependent manner[59]. Also, although EMT is activated in 
many tumor types, later stage markers such as vimentin are often not expressed, and 
hybrid phenotypes can increase cell motility both for individual cell migration and for 
collective migration[59]. Most low-grade tumors invade as cohesive multicellular 
aggregates of tumor cells, while high grade and mesenchymal tumors are more variable 
and present both collective migration and single-cell invasion of high EMT score 
phenotypes (Fig. 1.4)[65].  
The fate of circulating tumor cells (CTC) is dependent on the interactions maintained 
during transit through the circulatory system and at the pre-metastatic niche[66]. CTC 
must overcome physical challenges, namely loss of attachment to a substrate and sheer 
stress, as well as avoid immune clearance[66]. This can be achieved by association with 
platelets in the bloodstream (Fig. 1.4). These avoid tumor cell recognition and cytotoxic 
activity of Natural killer (NK) cells, an effect mediated by local production of TGFB1, 
which inhibits NK activity[67]. Additionally, the local TGFB1 secretion sustains the 
expression of EMT-promoting intracellular signaling, thus compensating for the lack of 
the stromal factors that contributed to invasion in the primary tumor lesion[68]. This is 
in line with the strong TGFB1 response expressing signature found in circulating BC 
cells[69]. Most invasive solid tumors, however, undergo primarily collective cell 
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migration, where groups of cells invade the surrounding stroma while still maintaining 
cell-cell contacts[65]. Clusters of tumor cells observed in circulation arise from 
multicellular cluster detachment from the primary tumor, rather than being aggregated 
within blood vessels, as observed in a mouse model for BC metastasis[70]. CTC clusters 
in this model presented 23 to 50-fold increased metastatic potential[70]. 
Metastasis is, nevertheless, a very inefficient process; experimental data suggests that 
only 0.01% of CTC achieve productive colonization of a distant organ[66]. Moreover, in 
the case of breast cancer, dormant micrometastasis relapse decades after the original 
tumor has been removed, highlighting the fact that invasion and successful outgrowth 
are separate phenomena[2]. The process of distant colonization appears to be 
dependent on the presence of cells with CSC properties, the ability of these cells to 
undergo mesenchymal to epithelial transition (MET), and on the development of a 
supportive microenvironment[66]. MET is influenced by the microenvironment at the 
pre-metastatic niche, namely by the presence of cancer-associated fibroblasts (CAF) and 
metastasis-associated macrophages, as well as environmental factors such as hypoxia 
and angiogenesis (Fig. 1.4)[71–74]. 
3.3 Therapeutic resistance 
Despite the advent of targeted molecular therapies, which often result from the 
dissection of the oncogenic pathways mediating malignancy, these remain in most cases 
poorly efficient and with mostly transient results[75]. Therapeutic resistance is, 
presently, the main obstacle in cancer treatment[76]. Identification of the underlying 
mechanisms is crucial to overcome current shortcomings improve clinical 
outcomes[76]. 
Cancer cell intrinsic mechanisms supporting acquired resistance include upregulation of 
drug efflux pumps and increased drug metabolism, as well as compensatory loss of 
specific oncogenes and emergence of enabling apoptotic defects[76]. Moreover, 
intrinsic intratumor heterogeneity across cancer types and tissue of origin also favors 
tumor evolution and therapeutic resistance[77]. Still, a great proportion of a tumors’ 
heterogeneity is a result of the cells present in its surrounding microenvironment, both 
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in terms of composition and activation states[78]. Extrinsic determinants such as 
cytokines and growth factors supplied by the cells in the TME play a significant 
contribution in tumor evolution and disease recurrence[77]. Deciphering the intricate 
networks established between the different players in the provides knowledge into the 
biological mechanisms behind acquired anticancer therapy resistance, as well as a 
rational for combinatorial therapies[76]. These have also been instrumental in 
uncovering important new targets for therapeutic intervention, namely 
immunotherapies[76]. 
3.4 Tumor microenvironment (TME) 
Tumors are shaped by environmental factors that enhance or dampen the effects of 
genetic and epigenetic alterations in the epithelial compartment[79]. The TME is a 
complex network of different cell types and soluble factors, intertwined within an ECM 
which provides physical support and directs cell signaling (Fig. 1.5)[76]. The 
acknowledgment of the dynamic and reciprocal heterotypic interactions between these 
different players has increased exponentially the complexity of cancer research. 
The TME has a profound impact on tumor progression, invasion, metastasis and, 
ultimately, patient prognosis and therapeutic response[78]. Under normal physiological 
conditions, the microenvironment maintains tissue architecture and restricts cell 
growth, thus inhibiting tumor initiation and progression[80]. The concept of “seed and 
soil”, first proposed by Stephen Paget in 1889, states that tumor cells may only lead to 
tumor outgrowth when a supportive microenvironment emerges[78]. Thus, while 
tumor initiation appears mostly inevitable, its progression into a malignant state could 
potentially be managed with full knowledge of the intervening partners[81]. 
Understanding the phenotypic and functional diversity of stromal and immune cells 
within the TME, as well as the different axis mediating this crosstalk, is essential for 
cancer prevention, detection and treatment[81]. The cellular players include 
endothelial and perivascular cells, adipocytes and fibroblasts, and engaged immune 
cells including Mϕ, dendritic cells, NK cells, myeloid derived suppressor cells (MSDC) 
and T and B cells. These acquire phenotypic and functional characteristics that are 
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distinct from their normal tissue resident counterparts and are reminiscent of a tissue 
recovering from wound healing[82]. On the other hand, deciphering this network 
provides cues to explain patients’ differential response to treatment and to develop 
therapies that prolong disease free survival and patient’s quality of life[83]. 
 
Figure 1.5: Different components of the tumor microenvironment. The balance between 
paracrine signaling and cell-cell interactions maintained at the tumor site dictate tumor 
progression and therapeutic response. Adapted from Quail et al., Nat. Med. (2013)[78]. 
Fibroblasts and Mϕ are key components within the TME and have been explored in the 
present work; therefore, are here reviewed further. 
3.4.1 The stromal compartment - fibroblasts 
Fibroblasts are a predominant cell type in the TME. Primary human fibroblasts have 
been described to inhibit tumor growth through direct cell-cell interaction as well as 
secretion of soluble factors[84,85]. However, upon contact with transformed cells, 
fibroblasts present an activated phenotype, with altered contractile and secretory 
characteristics when compared with fibroblasts from normal tissue[86], and a gene 
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expression profile similar to fibroblasts involved in wound healing[87,88]. Cancer-
mediated fibroblast “education” into CAF is achieved through the secretion of growth 
factors, such as TGFB1, PDGF and fibroblast growth factor 2 (FGF2), whose production 
is also induced on fibroblasts at later stages[82]. CAF accumulation at the TME 
correlates with increased risk of relapse and reduced anti-tumor immunity in several 
cancer types[79,89,90]. Besides prognosis, these can also instruct therapeutic response. 
A gene expression signature characteristic of reactive stroma could predict resistance 
to neoadjuvant chemotherapy[91], indicating that combination therapies with drugs 
targeting CAF could contribute to overcome therapeutic resistance. 
CAF influence most aspects of tumor biology. These have been functionally implicated 
in tumor formation[92], e.g., by contributing to genomic instability[81]. C-X-C motif 
chemokine ligand (CXCL) 12 and MMP secretion by CAF induces oxidative stress, leading 
to oncogenic transformation of epithelial cells[90,93,94]. CAF have also been linked with 
tumor subtype specification. A recent study reported that paracrine PDGFC signaling 
from BC cells induced hepatocyte growth factor (HGF), insulin like growth factor binding 
protein 3 (IGFBP3) and stanniocalcin 1 (STC1) expression on CAF, which resulted in 
specification of a BLBC (ER negative) subtype on the tumor epithelial compartment[95]. 
CAF also enhance most tumor hallmarks, including cell proliferation, ECM remodeling 
and inflammation[79]. The highly secretory phenotype of CAF provides cytokines and 
growth factors that aid tumor development. In particular, CAF are an important source 
of RTK ligands, which ultimately contribute to tumor resistance to therapy[96,97]. 
Stromal HGF production activates MET receptor and consequent downstream MAPK 
and PI3K/AKT signaling pathways, leading to tumor rescue from RAF inhibitors[98]. Also, 
PDGFC production was shown to induce resistance to antiangiogenic therapy in 
lymphomas[99]. Stromal secretion of vascular endothelial growth factor (VEGF) A, PDGF 
and FGF2 promotes recruitment and proliferation of endothelial cells, enhancing 
angiogenesis[82]. CXCL12 is one of the main mediators of CAF tumorigenic potential; its 
expression has been observed in several tumors and it can induce tumor cell growth 
directly or through angiogenesis induction[93]. Moreover, its binding to C-X-C motif 
chemokine receptor (CXCR) 4 induces resistance to the estrogen receptor 1 (ER) 
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inhibitor, fulvestrant, in ER+ BC cells and reduced sensitivity to chemotherapeutic drugs 
in NSCLC[76]. CAF are also the main source of ECM at the tumor site, namely collagen, 
fibronectin and laminin, and induce desmoplasia in advanced carcinomas[100]. CAF 
were also shown to induce suppression of antitumor immunity[101]. The dense matrix 
formed at the TME was proposed to limit lymphocyte access to tumor sites[102]. In 
another study, depletion of CAF correlated with increased differentiation of T helper 
(Th) 1 cells, reduced recruitment of M2-like M and was also correlated with increased 
CD8+T effector cell infiltration and activity[103]. Stromal expression of C-C motif 
chemokine ligand (CCL) 2, CCL3, CCL4, CCL5 has been shown to influence macrophage 
distribution and composition within the TME by recruitment of blood monocytes and 
immature myeloid cells[104]. CAF also contribute to the maintenance of an 
immunosuppressive TME through the production of CXCL8, IL4 and IL6, which polarize 
M towards an M2-like phenotype[105]. Adaptive immunity is also dampened by the 
stromal compartment. Tumor infiltrating CD8+ T cells are often located in the adjacent 
tumoral areas and in direct contact with the fibroblast population. These CAF can 
directly decrease tumor antigen-specific CD8+ T cells through cross-presentation of 
antigens in concomitance with immune checkpoint expression (programmed cell death 
1 ligand 2 - PDCD1LG2 - and Fas ligand  - FASLG)[106]. TGFB1 secretion also inhibits 
CD8+T and effector memory cells by inhibiting T cell receptor (TCR)-CD28 
signaling[107,108], and thymic stromal lymphopoietin (TSLP) directs T cell into a Th2 
phenotype[109]. 
It is important to note that CAF constitute a very heterogeneous population with 
multiple origins, and the effects of different CAF phenotypes are poorly 
understood[110]. Their intrinsic heterogeneity has been mainly studied in the context 
of single markers with a thoroughly elucidated functional role. CAF subpopulations 
expressing different levels of actin, alpha 2, smooth muscle, aorta (ACTA2), a broad 
activated fibroblast marker, can be found in wounds and sites of chronic inflammation. 
The tumor promoting activities of these CAFs have been dissected through co-
transplantation into mice with cancer cells, or by disrupting their phenotype with drugs 
and evaluating tumor progression[2]. These termed myofibroblasts are a prominent 
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stromal population in several tumor types that correlate with poor prognosis and lead 
to therapeutic resistance[79,111]. Caveolin 1 (CAV1) and/or PDGFR-expressing CAF also 
constitute prognostic markers associated with low survival[81,112]. However, studies 
conducted using single or double marker identification of CAF may underestimate the 
complexity of the stromal compartment. The concurrent analysis of fibroblast activation 
protein alpha (FAP) and ACTA2 found phenotypically distinct CAF subpopulations in 
pancreatic cancer, that presented different spatial distribution[113]. Another recent 
study, comparing tumor and adjacent tissue fibroblasts in different subtypes of BC, 
found four distinct CAF subtypes by quantification of six different fibroblast markers 
(FAP, integrin β1, ACTA2, protein S100-A4, PDGFRB and CAV1)[79]. The different 
stromal subtypes differed not only in biomarker expression, but also functional effect, 
and their prevalence and distribution was dependent on tumor subtype, histological 
grade and immune microenvironment[79]. A specific CAF immunosuppression 
signature, which correlated with higher macrophage and lower CD8+T cell infiltration, 
was found to be preferentially present in triple negative BC (TNBC) and may be a 
promising target for combination therapy[79].  
Not all CAF subpopulations aid tumor progression and since these are plastic cells, 
capable of acquiring multiple activating states, tumor promoting CAF phenotypes could 
be reversed[82]. However, we must better dissect stromal heterogeneity in the tumor 
milieu, which allied to the lack of functional biomarkers frustrates therapeutic 
strategies[103]. 
3.4.1 The immune compartment – macrophages 
Myeloid cell recruitment to the tumor site has several pro-tumorigenic purposes, 
including tumor progression, increased angiogenesis and immunosuppression. These 
cells are recruited from blood monocytes and differentiate into multiple cell subsets, 
including MSDC, dendritic cells and M, in response to TME stimuli produced by tumor 
and stromal cells[114]. Differentiated myeloid populations are a major source of 
endothelial, epithelial and stromal growth factors and matrix remodeling enzymes[2]. 
Clinical data shows that M are a prominent myeloid infiltrate in the majority of 
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malignant human cancers and exert a strong influence on the immunologic state at the 
tumor site[115]. With few exceptions, these generally imply a poor prognosis[116–122] 
and display pro-tumorigenic properties, with reduced antigenic presenting capacity and 
low cytotoxic function[114]. 
M encompass a diverse population of cells that is able to respond to inflammatory 
signals and tissue injury[115]. In steady-state, M mainly exert phagocytic functions, 
neutralizing threats to the host and scavenging cell debris, while serving as a bridge 
between the innate and the adaptive arms of the immune system[123]. While usually 
classified into M1 or M2 phenotypes depending on their functional role in human 
immunity, M are very plastic cells that change polarization state in response to 
environmental stimuli. Polarization involves remodeling in the cytokine secretion profile 
and in the expression of other signaling molecules, as well as surface receptors[114]. 
Several soluble factors produced by tumor and stromal cells were shown to induce 
monocyte recruitment, such as CCL2, colony stimulating factor 1 (CSF1), IL6, VEGF and 
PDGF[114,124]. The conditions observed at the tumor site that result of the aberrant 
metabolism of tumor cells, i.e. hypoxia, acidic pH and high lactate concentration, and of 
the release of danger signals by dying cells, triggers an inflammatory reaction 
resembling tissue damage[104,125,126]. In response, M polarize into a wound-healing 
and tissue-repair phenotype, with functions of debris removal, production of trophic 
signals and immunosuppression[127]. Additionally, TME cytokines, such as IL4, IL10 and 
IL13, produced by tumor and stromal cells, further contribute to polarize M into an 
M2-like pro-tumorigenic phenotype[128]. These tumor associated macrophages (TAM) 
secrete cytokines, growth factors, inflammatory substrates and proteolytic enzymes 
that contribute to cancer progression[128]. A lot of effort has been conducted towards 
dissection of the different identities and functions of M present in tissue during the 
steady-state and during sterile inflammatory conditions, such as cancer[115]. Although 
there are M populations present in all tumors, their amount, activation states and 
phenotypic markers differ from tissue to tissue and from patient to patient within the 
same tumor subtype[115]. TAM are traditionally associated with the M2 phenotype 
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since they suppress antitumor immunity through production of anti-inflammatory 
cytokines and contribute to the resolution of inflammation[114]. Nowadays, however, 
in light of the extensive network of transcriptional regulators at play during M 
polarization, characterization of M populations is based on a spectrum of phenotypes, 
that need further characterization[129]. Also, there have been additional M molecular 
phenotypes identified that do not reflect the current M1/M2 paradigm[114]. The first 
single-cell analysis of the innate immune compartment in human cancer patients 
evidenced distinct myeloid cell subsets, and their differential contribution to anti-tumor 
T cell immunity[130]. Understanding the changes occurring within these subsets in the 
initial tumor lesion can provide immunomodulatory strategies targeting the innate 
immune compartment, that may enhance response to checkpoint blockade 
therapies[130]. 
TAM’s pro-tumorigenic phenotype favors tumor growth by promoting tumor cell 
proliferation, invasion and metastasis, stimulating angionesis and ECM remodeling, and 
contributing to evasion from adaptive immunity (Fig. 1.6)[131]. At the invasive tumor 
front, several immune cells aid cell motility and invasion (Fig. 1.6 – E)[132,133]. Real-
time multiphoton imaging showed that M can associate with breast cancer cells at the 
tumor invasive edge and promote invasion[133]. Local production of TGFB1 and direct 
intercellular adhesion molecule 1 (ICAM1) / integrin subunit beta 2 (ITGB2)-mediated 
cell-cell contact by M2 M induces cell dissociation and migration of single cells at the 
tumor front[134]. Increased invasion and metastatic ability may also result from a local 
induction of EMT, which is potentiated by soluble factors produced by stromal and 
inflammatory cells at the tumor periphery[44]. In a paracrine and self-sustaining loop, 
TME IL4 induces epidermal growth factor (EGF) production by TAM, which induces CSF1 
secretion by tumor cells, further stimulating TAM survival and activation[132]. EGF, in 
turn, was shown to induce EGFR-mediated invasion by breast cancer cells, facilitating 
intravasation and promoting early metastasis (Fig. 1.6 – B, E)[132,135]. TAM, as well as 
other immune cells at the TME, secrete MMP, serine proteases and cathepsins that also 
facilitate invasion and metastasis by degrading ECM[114]. ECM remodeling can also 
cause the release of ECM-bound mitogenic factors that support angiogenesis (Fig. 1.6 – 
  Introduction 
 
23 
E, F)[103]. Direct secretion of prostaglandin-endoperoxide synthase 2 (PTGS2), FGF2, 
PDGFB1 and VEGF by TAM can also increase angiogenesis and promote endothelial cell 
survival[103]. Myeloid cells were shown to contribute to the development of a favorable 
pre-metastatic niche, enhancing tumor cell colonization of distant organs[136]. A 
distinct subset of metastasis-associated macrophages was identified at perivascular 
sites of lung metastasis of PymT BC mouse model, which was required for efficient 
metastatic seeding and growth[137]. Macrophage education at the pre-metastatic 
niche appears to be a result of systemic release of exosomes by tumor cells, at least in 
liver colonization[138]. Finally, TAM contribute to the development of an 
immunosuppressive TME by directly inhibiting CD8+ T effector cell function or by the 
secretion of cytokines that recruit other immunosuppressive immune cells (Fig. 1.6 – 
D)[114]. Overexpression of PDL1/2 and CD80/86, ligands of the inhibitory receptors PD-
1 and CTLA4, directly suppress cytotoxic CD8+T cell activity[114]. Production of 
cytokines and proteases, such as IL10, TGFB1, arginase 1 (ARG1), and prostaglandins, 
can also indirectly suppress T cell activation and proliferation (Fig. 1.6 – D)[114]. 
Thus, TAM infiltration can be a prognostic marker and a target for therapeutic 
intervention.  The functional significance of TAM infiltrates was demonstrated by gene 
knockout of macrophage growth factor CSF1, or its direct effectors, in the polyoma 
middle T (PyMT) mouse model of BC. The KO decreased the macrophage infiltrate, 
which resulted in slowed tumor progression and decreased metastatic 
behavior[139,140]. Also, inhibition of CSF1R signaling, and consequent decreased TAM 
density, promoted the recruitment of CD8+ T cells to the tumor site, leading to 
reduction of cervical and mammary tumor growth[141]. In parallel, overexpression of 
CSF1 in tumors stimulates macrophage infiltration, leads to tumor progression and 
metastasis, and is associated with poor prognosis in BC patients[140]. Finally, 
neutralizing antibodies against CSF1 or its receptor have the same effect in 
neuroblastoma mouse xenografts[142]. 
Promising results in both animal models and clinical trials targeting TAM suggests an 
important role in combination therapies[76]. Checkpoint blockade therapies focus on 
restoration of pre-existing antitumor cellular immunity, through rescue of exhausted 
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CD8+T cells or by depletion of regulatory T cells (Treg)[130]. However, the limited and 
heterogeneous response in different patients has sparked the need to develop 
accompanying strategies to further strengthen T cell responses. M cross-present 
foreign antigens and produce T cell differentiation cytokines, playing an important role 
in managing T cell function at the tumor site[130]. Therefore, controlling the 
macrophage compartment or changing macrophage phenotype at the tumor site may 
serve as a synergistic role in potentiating T cell targeting therapies[130]. Indeed, 
decreased macrophage infiltration leads to higher efficacy of immunotherapies[143]. 
Interestingly, PD1/PDL1 blockade has also been shown to restore TAM phagocytic 
capacity and reduce tumor growth of colorectal cancer in mice models[144]. 
 
Figure 1.6: Tumor-associated macrophages (TAM) role within the tumor microenvironment 
(TME). A - C) TME factors promoting the polarization of macrophages towards a tumor 
promoting phenotype; D – F) tumor promoting roles of TAM. Adapted from Ruffell et al., Trends 
Immunol (2012)[128]. 
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4. EXPERIMENTAL TUMOR MODELING 
Experimental tumor modeling has long supported the discovery of fundamental 
mechanisms of tumorigenesis and tumor progression, as well as provided platforms for 
the development of novel therapies. Still, the attrition rates observed today in clinical 
translation could be, in part, mitigated by more accurate recapitulation of 
environmental cues in research and preclinical models[145]. Since no model is a perfect 
representation of a real system, these must be chosen while considering the balance 
between their limitations and the necessary complexity to support the objectives of the 
study[146]. 
Two-dimensional (2D) cell culture systems provide the necessary throughput for fast 
screening of multiple compounds and key players in productive cell-cell 
interactions[98,147,148]. Nevertheless, these poorly predict drug response and lead to 
an overwhelming number of possible targets that, despite showing considerable 
efficacy in 2D culture assays or even animal models, are proven ineffective in clinical 
trials, prolonging patients’ survival by a few months or a couple of years in metastatic 
disease[81,145]. It is now evident that, in these systems, cell-plastic connections prevail 
over cell-cell and cell-ECM interactions[149]. Thus, the need for more predictive drug 
discovery assays has prompted advances in cell culture techniques that permitted a fast 
evolution of complex in vitro cell models attempting to recapitulate tumor 
architecture[150]. Pioneering work by Mina Bissel evidenced that complex systems can 
be exploited to uncover molecular mechanisms of tumorigenesis and invasion. Blockade 
of ITGB1 reverted the malignant phenotype of BC cells in a three-dimensional (3D), 
forming reverted acini and re-establishing CDH1/catenin beta 1 (CTNNB1) 
complexes[151]. This phenomena had not been observed in 2D cultures and showed 
that epithelial tumor cells can change polarity in a microenvironment-dependent 
manner[152]. 
Most used 3D tumor models rely on spheroids for culturing the epithelial 
compartment[153]. Spheroids have been used for drug screening and to study tumor 
cell function, angiogenesis and tumor-immune interactions[154]. These constitute high-
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throughput tools to select drug candidates and decrease animal use, as they present 
higher resistance to treatment, thus better resembling the drug response observed in 
solid tumors[155]. These are formed by spontaneous aggregation of cells in culture and 
present characteristics resembling the in vivo tumors, namely physical change in cell 
structure and polarity[152], tensile forces[156] and ECM production[157,158]. Also, 
these models maintain cell-cell interactions, gradients of nutrients, metabolites, oxygen 
and also ECM accumulation[159,160]. Finally, extensive studies have shown that tumor 
cell lines cultured under 3D conditions exhibit gene expression profiles closer to patient 
samples[154,161]. 
The thorough establishment of the influence of the TME on tumor progression and 
therapeutic response has spirited the development of in vitro models where some of 
these interactions can start to be dissected and exploited. Most heterotypic cell cultures 
incorporate CAF, which promote an inflammatory microenvironment and lead to drug 
resistance, though other cell types have been used, namely mesenchymal stem 
cells[162]. The fast development of immunotherapies, however, is driving the need for 
preclinical models that incorporate the immunological state of the TME, while 
maintaining compatibility with drug screening platforms and allowing straightforward 
functionality assessment[86]. 
Innovative strategies for research and preclinical studies of tumor-stroma-immune cell 
dynamic interactions pose a difficult challenge for the tumor modeling field[86]. 
Traditional co-culture techniques have brought significant insights into the crosstalk 
between cells from the TME. Conditioned media experiments have been extensively 
employed to study interactions between different cells; however, these preclude direct 
cell-cell interactions and dynamic crosstalk between the different cell types. Indirect co-
cultures, on the other hand, allow for reciprocal and dynamic crosstalk between the 
different components but still, only through soluble factors[163]. Finally, direct co-
culture assays add an extra layer of complexity on the readouts since either gene 
expression or protein analysis on individual cell subsets requires previous separation of 
the cell types; thus most analysis is ultimately based on imaging and secreted factors 
(Fig. 1.7 – A)[163]. Nevertheless, the contribution of cell-cell and cell-ECM components 
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is crucial for the tumorigenic phenotype and thus such interaction should be included 
in preclinical models. Several in vivo models have also been used to study tumor-TME 
interactions. Most relevant in vivo tumor-bearing models include patient- or cell line-
derived xenografts (PDX/CDX), and genetically engineered mouse models 
(GEMM)[164]. Heterotypic implantation of human tumor cells in immunodeficient 
mouse models constitute effective alternatives to study tumorigenesis of specific tumor 
subtypes via genetic, phenotypic and functional analysis[164]. However, the lack of 
immune subset and the presence of murine stromal compartment render any 
considerations on the tumor-immune interactions and its impact on tumor progression 
unfeasible[86]. Xenografts that have incorporated the human immune compartment do 
exist, but are expensive and pose ethical dilemmas, while still not accurately translating 
results into the human setting[147]. GEMM, on the other hand, are very useful to study 
tumorigenesis of specific cancer subtypes. Here, the tumor-TME interactions are 
studied within a murine system, which may not represent the human situation[165–
167]. Anti-CSF1 therapeutic approaches, for example, lead to complete tumor 
regression in mouse models of solid tumors but show lack of efficacy in human clinical 
trials[168]. 
3D heterotypic cellular models may provide the necessary complementary solution in 
terms of functionality, complexity and throughput, between in vivo experimental 
models or standard in vitro approaches and clinical oncology (Fig. 1.7)[86]. Spheroids 
appear uniquely qualified to decipher tumor-immune interactions. Transcriptional 
analysis of mesothelioma spheroids vs monolayers showed that the majority of 
upregulated genes are related with immune response, wound healing, lymphocyte 
stimulation and response to cytokine stimulation, while downregulated genes mainly 
include promotion of apoptosis[147,169]. Early reports show that cancer spheroids 
show increased migratory capacity when co-cultured with M2-like M, resembling to 
some extent the effects described for TAM in human tumors[170]. Moreover, the 
reciprocal crosstalk between breast cancer spheroids from different subtypes and 




Figure 1.7: Different strategies to study tumor-immune interactions. A) 
Tumor-immune cell 2D direct co-culture; B) Tumor-immune 3D co-
cultures based on spheroids, evidencing the lower ability to stimulate 
cytokine release by effector cells, as compared to 2D co-cultures. 
Different immunosuppressive characteristics of tumor spheroids are also 
depicted; C) In vivo mouse models evidencing the lower immunogenicity 
of tumor spheroids transplanted into immunocompetent mice, as 
compared to tumor single cell suspension. Adapted from Hirt et al., Adv. 
Drug Deliv. Rev (2014)[86]. 
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The co-culture with breast cancer spheroids from more aggressive phenotypes, namely 
BLBC, induced a pro-tumorigenic phenotype in the M population, with consequent 
increased invasive potential for the tumor cells[171], features already described for 
these tumors in vivo[172]. Tumor spheroids also present diminished antigen presenting 
capacity and decreased proliferation (Fig. 1.7 – B)[86]. This leads to lower 
immunogenicity when compared to monolayers, decreasing tumor cells sensitivity to 
lymphocyte effector functions, which is also a prominent feature in different solid 
tumors in vivo (Fig- 1.7 – C)[86,103,147]. Additionally, the high lactate production is a 
key mechanism of action leading to an immunosuppressive TME in models 
encompassing tumor spheroids (Fig. 1.7 – B)[86]. 
Finally, the use of tumor biopsies or resected tumor sections embedded in a matrix can 
maintain heterogeneity of tumor cell populations and be a potential screening tool for 
patient-specific therapies[154]. Although these have been exploited, their application 
for drug discovery faces technical problems and limitations in sample material[150].  
5. CANCER GENE THERAPY 
Cancer diagnostics and therapeutics have evolved tremendously in the past decades, 
and now include strategies to target cancer cell intrinsic genetic aberrations and cell 
extrinsic mediators of malignancy[173]. Nonetheless, uncovering promising targets is 
not sufficient, efficient delivery platforms are still a bottleneck in the implementation 
of innovative therapies[174]. After many years of intense research delayed by 
significant setbacks related with negative outcomes in clinical trials, gene therapy is 
emerging as an important therapeutic approach[175]. Recent progress has been 
leveraged by the better understanding of the viral vector biology and a deeper 
knowledge of the target cells[175]. Currently, gene therapy-based treatments are 
approaching clinical approval by FDA and EMA for a myriad of diseases, from inherited 
immune disorders, hemophilia, eye and neurodegenerative disorders and lymphoid 
cancers[175]. Also, there is gene therapy product based on adeno-associated viral (AAV) 
vectors (Glybera) with granted marketing authorization in the European Union for the 
treatment of lipoprotein lipase deficiency[176]. 
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For cancer gene therapy approaches to be successful, the development of gene delivery 
vectors that can safely and efficiently be used to bring genetic material into target cells 
is needed[177]. Non-viral vectors are easy to produce and readily amenable to 
engineering; however, these are difficult to deliver to target cells[177]. Viral vectors, on 
the other hand, can be exploited for their natural ability to efficiently reach and infect 
target cells. The prevalence of gene therapy clinical trials directed at cancer have long 
been focused on oncolytic viruses, which include adenovirus, herpes simplex virus, and 
reovirus[177,178]. Nevertheless, many viral vectors have been tested as gene delivery 
platforms, including adenovirus, retrovirus, vaccinia virus, herpesvirus, and AAV. Gene 
therapy approaches to target cancer cover a wide variety of strategies. These include 
delivery of suicide genes, such as the herpes simplex virus-thymidine kinase system and 
polyomavirus middle T antigen; vascular reprogramming by delivery of anti-angiogenic 
factors, such as PEDF, endostatin 34, Kringle 5 and Kallistatin; and strategies to activate 
the immune system, such as the delivery of cytokines or immunogenic cell surface 
molecules and tumor antigens[177].  
5.1 Adeno-associated Viral Vectors (AAV) 
The in vivo gene therapy field is currently dominated by recombinant adeno-associated 
viral vectors (rAAV). These have been increasingly used in clinical trials due to their 
safety profile and persistent transgene expression in vivo, when administered both 
locally and systemically[179].  
The rAAV are engineered from adeno-associated viruses, which are nonpathogenic, 
naturally replication-deficient and mostly non-integrative. These characteristics greatly 
reduces the risks associated with their clinical application but also decreases the long-
term expression potential in proliferative cells[180]. In central nervous system (CNS) 
disorders, namely congenital blindness, Parkinson´s disease and Leber’s congenital 
amaurosis, AAV-based gene replacement therapies have successfully translated the 
results achieved in preclinical tests to humans[179,181,182]. This most likely reflects 
the good tropism found in some AAV variants towards CNS, together with the fact that 
retinal space is an immunoprivileged site[179]. Since humans are natural hosts for 
  Introduction 
 
31 
adeno-associated virus, most people already have pre-existing humoral and cellular 
immunity against the AAV capsid, which reduces clinical efficacy[180]. Successful clinical 
translation of AAV-based therapies was preceded by a better understanding of anti-AAV 
immune responses, as well as by the development of strategies to circumvent such 
responses[175]. Over the years, several avenues to engineer AAV´s capsid have allowed 
the development of less immunogenic variants, as well as vectors presenting tropism 
better suited to the specific needs of the therapeutic target. Increased understanding 
of the AAV capsid structure, coupled with the presence of a known receptor at the 
target cell of interest enable rational design approaches[183]. The display of high 
affinity ligands for HER2 at the VP2 capsid protein of AAV2 increased their specificity for 
this BC subtype, which may be used in targeted therapies[184]. On the other hand, 
when there is no knowledge on the receptor to target, directed evolution approaches 
have been employed. Here, selective pressure is applied to identify relevant AAV 
variants[183]. For example, using different pools of human anti-AAV antibodies, several 
rounds of selective pressure enabled the identification of an AAV2 variant that could 
tolerate higher levels of neutralizing antibodies[185]. 
The delivery of high titer and high quality rAAV batches to meet clinical demands is 
supported by continuous improvement of upstream manufacturing and downstream 
purification processes[186]. The development of scalable platforms that allow 
generation of large quantity of high quality AAV batches are necessary to accommodate 
later stage clinical trials[187]. Manufacturing processes for rAAV are mostly based on 
two systems: stable producer cell lines and transient production systems[188]. 
Transient production involves either co-transfection of several plasmids or co-infection 
with different viruses that provide the helper functions and the vector construct, 
necessary to replicate and package the rAAV genome[179]. Laboratory scale platforms 
are mainly based on transfection of mammalian cells on 2D culture systems[179]. These 
are faster to implement and, by avoiding the use of helper virus, render the process 
much less time-consuming[186]. These systems enable rapid screen of multiple 
candidate vector construct for early assessment of lead candidates and can ensure 
production at preclinical and phase I/II clinical trial scale[186]. Several options for 
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scalability are already available including the use of multi-tray cell factories, roller 
bottles and suspension cultures[188]. Large scale production systems are based on 
suspension cultures of mammalian or insect cells[188]. Bioreactors routinely used for 
large scale suspension cultures include stirred-tank and WAVE bioreactors[188]. Insect 
cells in association with the baculovirus expression vector system (IC-BEVS) are 
currently one of the most used platforms for large scale rAAV production[189]. Insect 
cell-based platforms are scalable and GMP-compatible, since they achieve high cell 
density in suspension in serum-free conditions[188]. IC-BEVS can currently yield 
production batches suitable for later stage clinical trials and commercial use, with 
multiple products, mostly vaccines and gene therapy vectors, already approved for 
human and veterinary use, including Glybera[190]. 
6. AIMS AND SCOPE 
The overarching aim of this thesis was to develop strategies that could improve the 
clinical translation of tumor biology insights. The work was divided into two main 
sections: A) development of therapeutic strategies to target cancer genetic 
vulnerabilities and B) development of 3D cellular models that incorporated the crosstalk 
between tumor cells and cells from the tumor microenvironment. 
In Chapter I, the state of the relevant to the present work was reviewed.  
In the first part of the work (A), we took advantage of previously described genetic 
vulnerabilities of BLBC to pursue the development of a targeted therapeutic approach 
for this BC subtype. The lack of targeted therapies for BLBC does not reflect an absence 
of potential molecular targets. These do, however, need to be assessed for their 
preclinical efficacy to accurately evaluate their clinical potential. Therefore, in Chapter 
II, we developed an rAAV-based gene therapy for the delivery of shRNA molecules 
targeting BLBC survival genes. To assess its effect, two different BLBC cell lines were 
transduced with the developed rAAV vectors and their effect on tumor cell viability and 
apoptosis induction was evaluated. Also, using an in vivo preclinical model – BLBC 
mouse xenografts - we planned to assess the effect of the developed therapeutic 
approach in BLBC cancer progression, by measuring the tumor volume over the course 
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of the treatment. Also, given the broad tropism of AAV2 serotype, and in order to avoid 
unspecific infection of non-relevant tissues in vivo, it was important to design a strategy 
to restrict AAV2 tropism towards BLBC. For this, in Chapter III, sequential rounds of 
infection were conducted using different BLBC cell lines in an attempt to recover the 
variants with higher specificity. Thus, this would allow the development of a therapeutic 
strategy with specific toxicity for BLBC and that could be applied systemically.  
The increasing realization that TME cues play a decisive role in the outcome of cancer 
drug response, urges its integration in preclinical tumor models. Several anticancer 
therapies require the presence of an engaged immune system to enhance their efficacy. 
These include untargeted approaches, namely chemo- and radiotherapy, as well as 
targeted molecular approaches aiming at inducing tumor cell death. Therefore, in 
Chapter IV, we aimed at developing a 3D co-culture model that incorporated tumor, 
stromal and myeloid cell compartments. We hypothesized that by co-culturing relevant 
cell types present in the TME, and allowing cell-cell communication through both direct 
cell-cell contact and soluble factors, we would be able to mimic certain aspects of the 
TME. The inclusion of macrophages, in particular, could lead to the development of an 
immunosuppressive TME, present at NSCLC. Hence, a more accurate preclinical tumor 
model for both disease modeling and drug screening applications could be developed. 
This model was based on alginate microencapsulation of the different cells, which were 
cultured under stirred conditions. The model was characterized phenotypically and 
functionally, by treatment with both chemo and immunomodulatory challenges. 
Finally, in Chapter V, a general discussion of the work is presented, together with 
perspective on how this can impact future approaches in cancer research. 
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ABSTRACT 
Adeno-associated viral vectors (AAV) for gene therapy applications are gaining 
momentum after the clinical approval of Glybera, with more therapies moving into later 
stages of clinical development and towards market approval, namely for cancer therapy. 
The development of cytotoxic vectors is often hampered by side effects arising when 
non-target cells are infected, and their production can be hindered by toxic effects of 
the transgene on the producing cell lines. In this study, we evaluated the potential of 
rAAV-mediated delivery of short hairpin RNAs (shRNA) to target basal-like breast cancer 
(BLBC) genetic vulnerabilities. Our results show that by optimizing the stoichiometry of 
the plasmids upon transfection and time of harvest, it is possible to increase the viral 
titers and quality. All obtained rAAV-shRNA vectors efficiently transduced the BLBC cell 
lines MDA-MB-468 and HCC1954. In MDA-MB-468, transduction with rAAV-shRNA 
vector targeting the PSMA2 was associated with significant decrease in cell viability and 
apoptosis induction. Importantly, rAAV2-PSMA2 also induced reduced tumor growth in 
a BLBC mouse xenograft model, thus representing a promising therapeutic vector 
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1. INTRODUCTION 
Gene therapy has the opportunity to expand beyond conventional drug based 
therapeutics and deliver a targeted treatment through regulation of endogenous 
genes[1]. As our knowledge on cancer´s onset and progression evolves, tumor-specific 
phenotypic characteristics are uncovered that can be explored in this context, to 
achieve higher specificity and potency of the developed therapies[2]. Basal-like breast 
cancer (BLBC) patients can greatly benefit from the development of such therapies. 
Although this subtype represents up to 20% of worldwide breast cancer (BC) incidence, 
it is responsible for a disproportionate number of deaths as it often leads to relapse with 
distant metastasis[3]. The lack of molecular markers and deficient characterization, 
impaired by an heterogeneous molecular presentation, leads to lack of targeted 
therapies and leaves clinicians with cytotoxic chemotherapeutic drugs as the only 
treatment option[3,4]. Standard treatment for these patients, namely surgery, radiation 
and chemotherapy, often fails to completely eradicate the disease, is incapable of 
maintaining sustained protection, and is accompanied by serious side effects, such as 
cytotoxicity to non-cancerous cells[5,6]. Therefore, there is a strong unmet medical 
need for targeted therapies for BLBC with improved clinical efficacy, targeted effect 
with lower side effects, and longer patient survival times[6,7]. A lot of effort has been 
conducted towards the discovery of actionable molecular targets for this disease[8]. 
Recently, Petrocca et al conducted a genome-wide small interfering RNA (siRNA) screen 
to identify selective genetic vulnerabilities causing lethality in this BC subtype[9]. 
Although promising, these leads still face considerable challenges reaching the clinic due 
to ineffective delivery platforms[10]. 
Recombinant adeno-associated viral (rAAV) vectors have been increasingly successful 
as gene therapy delivery platforms and have proven to be a promising approach to treat 
a variety of human diseases[11–13]. The increasing number of preclinical studies and 
human clinical trials has demonstrated their favorable safety profile, efficacious gene 
delivery, and robust and persistent transgene expression in vivo, with manageable 
immune response and minor adverse effects upon injection[6,14,15]. In fact, an rAAV1-
based vector for the treatment of a lipoprotein lipase deficiency became the first 
Chapter II 
48 
commercially-approved gene therapy product for clinical applications by the European 
Commission[16]. 
rAAV vectors’ potential for cancer applications has also been demonstrated in several 
in vitro cancer studies, in vivo pre-clinical cancer models, and clinical trials, with a wide 
variety of approaches, such as the delivery of anti-angiogenesis factors (PEDF, 
endostatin 34, Kringle 5, Kallistatin), suicide genes (HSV-TK system and polyomavirus 
middle T antigen), immunostimulatory molecules (TRAIL, Interferons, Interleukins), 
DNA-encoded small RNA molecules for post-transcriptional regulation of oncogenes, 
immunogenic cell surface molecules and tumor antigens[5,6,17]. 
Herein we describe an rAAV-based therapeutic approach to target BLBC. Signature 
genetic dependencies previously identified for this BC subtype (i.e. MCL1, PSMA2 and 
PSMB4)[9] were targeted using rAAV-mediated delivery of shRNA. Consequent 
downregulation of the target genes led to a decrease in cell viability and induced 
apoptosis in BLBC cell lines. Furthermore, intratumoral injections of rAAV vectors 
targeting PSMA2 resulted in slowed tumor growth in a BLBC xenograft model. 
Moreover, our results indicate that optimization of plasmid stoichiometry upon 
transfection and time of harvest should be done in a transgene dependent manner, with 
the goal of circumventing potential cytotoxic effects of the transgene in the producer 
cell line and yield rAAV batches of higher quality. 
2. MATERIALS AND METHODS 
2.1 Cell culture 
HEK293T (ATCC CRL-3216™) and HT1080 cells (ATCC® CCL121) cells were cultured in 
high glucose (4.5 g/L) DMEM supplemented with 10% (v/v) fetal bovine serum (FBS). 
The basal breast cancer cell lines HCC1954 and MDA-MB-468, kindly provided by 
professor Judy Lieberman (Harvard Medical Scholl, USA) were cultured in RPMI 1640 
medium supplemented with 10% (v/v) FBS, 6 mM HEPES and 5 µM 2-Mercaptoethanol. 
Media and cell culture reagents were from Gibco Life Technologies. Cells were 
incubated at 37 °C in a humidified atmosphere with 5% CO2 in air. 
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2.2 Construction of pAAV-shRNA plasmids 
An AAV2 vector plasmid carrying a CMV-promoter driven GFP gene flanked by ITRs, and 
a puromycin resistance gene under the control of a hEF1 promoter outside the AAV2 
expression cassette with no shRNA (pAAV-Puro) was generated based on the AAV2 
vector construct pAAV-MSC-CMV-eGFP-CytbAS (kind gift from Prof. U. Michel, 
University Medicine Göttingen, Germany), after removal of the extra CMV promoter. To 
construct the pAAV2-shRNA vectors, DNA fragments containing the H1 promoter, gene 
specific or control scramble shRNA sequences, and the BstBI and HindIII restriction sites, 
at the 5´and 3´extremities, respectively, were chemically synthesized (GenScript) and 
cloned into the BstBI/HindIII site of pAAV-Puro inside the AAV2 expression cassette. The 
generated pAAV-shRNA plasmids were amplified in E. coli Stbl3 cells (Invitrogen), and 
their sequence integrity and orientation were confirmed by restriction analysis and 
sequencing. Gene specific shRNA sequences were obtained from the RNAi consortium 
database (http://www.broadinstitute.org/rnai/public/). The scramble control shRNA 
sequences, not targeting any known human or mouse genes, were from Sigma. The 
shRNA catalog numbers are: PLK1shRNA: TRCN0000006247; MCL1shRNA: 
TRCN0000196390; PSMA2shRNA: TRCN0000003879; PSMB4shRNA: TRCN0000003914; 
Ctrl1shRNA: SHC202; and Ctrl2shRNA: SHC016.  
2.3 Production, purification and titer determination of rAAV-shRNA 
vectors 
rAAV-shRNA vectors were produced in HEK293T cells by 2- or 3-plasmid transfection 
system using 5 g DNA/1x106 cells, with linear polyethylenimine (PEI; Polysciences) or 
CaPO4 as transfection reagents. In the 2-plasmid system HEK293T cells (seeded at 4-
5x104 cell/cm2 20-24h before) were co-transfected at 70-80% confluency with individual 
pAAV-shRNA plasmids, generated above, plus the pDG plasmid[18], encoding the rep 
and cap genes and the adenovirus encoding products essential for AAV vector 
production, using different plasmid ratios as indicated below. 3-plasmid transfection 
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was performed with plasmids: pAAV-shRNA, pAAV-Helper - encoding adenovirus gene 
products required for the production of infective AAV particles, and pAAV-RC - encoding 
the rep and cap genes (necessary trans-acting elements for replication and packaging of 
the viral genome) (all from Stratagene/Agilent), at a plasmid molar ratio of 1:1:1. All 
plasmids, except pAAV-shRNA, were amplified in E. coli DH5 cells (Invitrogen). Plasmid 
DNA was purified with the EndoFree plasmid kit from Qiagen, as per supplier´s 
instructions. Transfections with the CaPO4 method were performed using the Calcium 
Phosphate Transfection Kit from Sigma (CAPHOS) as per kit´s instructions. Transfections 
of HEK293T cells with PEI were performed as per standard protocols using optimized 
DNA:PEI ratio of 1:1.8 (g), as previously described[19]. 48-72h post transfection, cells 
were lysed with 0.1% Triton-X100 (Sigma), releasing the intracellular vectors into the 
supernatant. Media with lysed cells was collected and incubated with 30 unit/ml 
Benzonase® nuclease (Merck Millipore) and sterile 2 mM MgCl2 (Sigma) for 1h at 37C, 
for removal of host cell and unpacked DNA. The solution was clarified by centrifugation 
(4000xg/30min/40C) and the vector-containing supernatant (primary viral stock) was 
filtered through 0.45-m pore size filters (Merck Millipore). Purification of the different 
rAAV-shRNA vectors was performed by affinity chromatography using the AVB 
Sepharose High Performance resin (GE Healthcare), according to manufacturer’s 
instructions. Purity was monitored by SDS-PAGE followed by InstantBlue™ and 
endotoxin content assessed with the chromogenic LAL test kit (Endosafe-PTS). All 
vectors used in this study passed the endotoxin test. 
Viral productivities were assessed in primary viral stocks and purified vectors. Viral 
particle (vp) titration was performed using the AAV titration kit ELISA (PROGEN 
Biotechnik GmbH), according to manufacturer’s instructions. For rAAV-shRNA vector 
genome (vg) quantification, viral DNA was extracted and purified with the high pure 
viral nucleic acid kit (Roche). Vg titer was quantified by real-time PCR quantification 
(qPCR) of encapsidated CMV promoter DNA fragment driving the expression of the GFP 
transgene, in at least 3 different serial dilutions of extracted viral DNA stocks, against a 
linearized pAAV-Ctrl1shRNA plasmid DNA standard curve. Eight serial dilutions of the 
plasmid standard (containing 108, 107, 106, 105, 104, 103, 102, and 101 copies of plasmid 
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DNA) were used to generate a standard curve for absolute quantification of vector 
samples. All reactions were performed in triplicate using CMV specific primers (Forward: 
5´-GCGCCTCTTATACCCACGTAG-3' and reverse: 5´-TAACACCGCCCCGGTTT-3´) and the 
SYBR Green I Master mix (Roche). Analysis of qPCR results was carried out with LC480 
software. Infectious particle (ip) titration was performed in HT1080 fibrosarcoma cells 
as previously described[19]. Briefly, cells were transduced at 50% confluency with serial 
dilutions of the viral stocks for 2h. After 48h incubation in complete media cells were 
harvested and the percentage of GFP+/infected cells was quantified by flow cytometry 
(Cyflow Space, Partec).  
2.4 pAAV-shRNA plasmid transfection 
HEK293T cells at 60-70% confluency were transiently transfected with individual pAAV-
shRNA constructs at 5 µg DNA per 1x106 cells using PEI as transfection reagent, at a 
DNA:PEI ratio of 1:2 (µg). After 8h incubation, medium was replaced, and cells further 
cultured. After 24-48h, cells were imaged by fluorescence microscopy for the expression 
of GFP transgene and harvested for RNA extraction for gene expression studies and GFP+ 
cell quantification by flow cytometry (Cyflow Space, Partec).  
2.5 rAAV-shRNA vector transduction and Fluorescence activated cell 
sorting 
HCC1954 and MDA-MB-468 cells at 60-70% confluency were transduced with individual 
rAAV2-shRNA vectors at a multiplicity of infection (MOI) of 4x104 vg/cell in 2% serum 
containing media. After 8h incubation, medium was replaced by complete media and 
transduced cells were FACS sorted for GFP expression 24h and 48h thereafter. Following 
FACS isolation, cells were immediately used for RNA extraction for gene expression 
studies or further cultured for viability and apoptosis assays. Sorting was conducted at 
the Instituto Gulbenkian de Ciência Flow Cytometric facility in Moflo (Beckman Coulter) 
and FACSAria (Becton Dickinson) cytometers. 
2.6 Gene expression analysis 
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Total RNA from cells was extracted with Qiagen RNeasy Mini Kit as per manufacturer´s 
instructions with DNAse digestion. cDNA was synthesized, from equal amounts of RNA, 
by reverse transcription using the Advantage RT-for-PCR kit (Clontech Laboratories, 
Mountain View, CA), or the High Fidelity cDNA Synthesis Kit (Roche), as per the 
manufacturer's Instructions. Gene expression was quantified on Roche LightCycler 480 
(LC480) using gene specific primers and the SYBR Green I Master mix (Roche). All 
experiments were performed in triplicate and the melting-curve data were collected to 
check product specificity. mRNA transcripts were normalized to both hypoxanthine 
phosphoribosyltransferase 1 (HPRT1) and ribosomal protein L22 (RPL22) mRNA levels in 
the same sample, and the results were calculated as fold change relative to control cells 
using the advanced relative quantification method from the LC480 software. The 
primers used were (forward and reverse, respectively): HPRT1:  5´-
CCTGGCGTCGTGATTAGTGAT-3´ and 5´- AGACGTTCAGTCCTGTCCATAA-3’; MCL1: 5´-
TGCTTCGGAAACTGGACATCA-3´ and 5´- TAGCCACAAAGGCACCAAAAG-3´; PLK1: 5´-
AAAGAGATCCCGGAGGTCCTA-3´ and 5´- GGCTGCGGTGAATGGATATTTC-3´; PSMA2:  5´-
GAGCGCGGGTACAGCTTTT-3´ and 5´- ACCACACCATTTGCAGCTTTA-3; PSMB4:  5´-
GAAGCGTTTTTGGGGTCGC-3´ and 5´-GAGTGGACGGAATGCGGTA-3; RPL22:  5´-
CACGAAGGAGGAGTGACTGG-3´ and 5´-TGTGGCACACCACTGACATT-3´. 
2.7 Cell viability and apoptosis 
To investigate the effects of rAAV-shRNA vectors on cell viability, sorted-transduced 
cells were plated in 96-well plates at different cell densities and incubated for 48-120h. 
After each 24h incubation period, cell viability was assessed using the PrestoBlue™ cell 
viability reagent (Life Technologies), according to the manufacturer’s instructions. For 
apoptosis assays transduced cells were plated in 24-well plates, at different cell 
densities, and the number of apoptotic cells was determined by flow cytometry using 
the FLICA apoptosis kit (Immunochemistry Technologies) as per the manufacturer’s 
instructions. 
2.8 Mouse xenografts and vector delivery 
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All animal experiments were carried out in accordance with the Guidelines for the Care 
and Use of Laboratory Animals, directive 86/609/EEC. Human BLBC model was 
established in N:NIH(s)II:nu/nu nude mice with MDA-MB-468 cells. Briefly, 2x106 MDA-
MB-468 cells were injected into the mammary fat pad of Female N:NIH(s)II:nu/nu nude 
mice. Three to four mice were kept per cage, with food and water ad libitum, and 
examined daily. Mice weight and tumor volume were measured twice a week until 
tumors reached an average volume of 100-150 mm3. Mice were then distributed into 
different experimental groups, with equal average tumor volume, for treatment 
initiation. rAAV2-shRNA intratumoral injections were performed twice a week, for 3-4 
weeks. Tumors were measured in two perpendicular dimensions and the volume was 
estimated by the formula [volume = (length) x (width)2/2] for approximating the volume 
of an ellipsoid. 
3. RESULTS 
3.1 Development of an rAAV vector expressing eGFP and an shRNA 
targeting BLBC genetic vulnerabilities  
3.1.1 Design and validation of AAV-shRNA plasmids 
Building on the overrepresentation of proteasome machinery leads identified as BLBC 
intrinsic vulnerabilities in a previous study[9], two proteasome subunits were chosen as 
potential targets – proteasome subunit alpha 2 (PSMA2) and proteasome subunit beta 
4 (PSMB4). Another persistent susceptibility identified was MCL1, BCL2 family apoptosis 
regulator (MCL1), an anti-apoptotic protein that was the third target chosen for the 
present study. shRNA sequences targeting these genes (MCL1sh, PSMA2sh and 
PSMB4sh) were obtained from a publicly available database 
(https://www.broadinstitute.org/rnai/trc). An shRNA targeting polo like kinase 1 (PLK1), 
a Ser/Thr protein kinase highly expressed during mitosis[20], was also obtained. 
Inhibition of this protein has been previously shown to decrease proliferation and 
induce apoptosis in cancer cells[21,22], thus PLK1sh was used as positive control. 
Additionally, two scramble shRNA (Ctrl1sh and Ctrl2sh), with no known targets in 
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human or mouse cells, served as negative controls. All shRNA sequences were cloned 
into a pAAV expression vector, co-expressing an eGFP reporter gene to facilitate the 
monitoring of target cell transduction. Validation of shRNA knockdown efficiency of the 
different plasmid constructs was assessed by transient transfection of HEK293T cells. 
Target gene knockdown efficiencies ranging from 40 to 90% were obtained, depending 
on the shRNA (Fig. 2.1), showing that the designed sequences caused potent and 
specific target gene silencing. 
3.1.2 Platform implementation for endotoxin-free rAAV-shRNA vector 
production 
Production processes based on transient transfection of HEK293T cells constitute a 
versatile platform, that enables a rapid performance screen of multiple rAAV vectors for 
the most promising lead[14,23,24]. Therefore, for production of rAAV-shRNA vectors, 2 
and 3-plasmid transfection using CaPO4 or PEI as transfection agent, were tested.  
 
Figure 2.1: Validation of AAV-shRNA plasmids for downregulation of BLBC genetic 
vulnerabilities. qRT-PCR analysis of PLK1, MCL1, PSMA2, PSMB4 gene expression 24h 
post-transfection of HEK293T cells with the different plasmid constructs. mRNA levels 
were normalized against the housekeeping RPL22 mRNA levels within the same 
sample and are shown as fold change relative to the respective levels in control cells 
transfected with scramble negative control Ctrl1sh plasmid. 
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Initial assessment of vector productivity was conducted using rAAV-Ctrl1sh to 
circumvent effects arising from target gene knockdown on the production cell line 
(HEK293T), which could mask the results. As observed in Fig. 2.2 – A, there were no 
significant differences in the productivity (vg/cell) obtained with the two transfection 
reagents tested. While low cost and high transfection rates can make CaPO4 the obvious 
choice for small scale productions, the similar yields obtained in these preparations led 
us to pursue with PEI transfection, for easier scalability and more consistent results[24]. 
Regarding the transfection systems, as observed in Fig. 2.2 – B, 2-plasmid transfection 
system delivered significantly higher production yields. On average, the viral vector 
titer, as per vg/cell, was up to 5-fold higher with the 2-plasmid system relative to the 3-
plasmid. 
 
Figure 2.2: Platform implementation for rAAV-shRNA vector production. Evaluation 
of rAAV vector productivity following HEK293T cell transfection using A) different 
transfection agents (CaPO4 vs. PEI) and B) different transfection conditions (2- vs. 3-
plasmid system). *, p <0.05, statistical significance was determined using two-tailed 
Student´s t-test. 
Quality control of each AAV vector preparation in terms of total viral particles, packaged 
viral genomes and infectious particles is critical before potency assays are conducted, 
since different rAAV variants produced potentially have different ratios of the referred 
parameters. Standard upstream methods for rAAV vector production combine the 
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plasmid carrying the transgene (pAAV) and the helper/packaging plasmid (pDG) in a 1:1 
equimolar ratio, and set time of harvest (TOH) at 72 hours post transfection (hpt). As 
observed in Table 2.1, this combination led to a high vp/vg ratio.  
Table 2.1: Optimization of plasmid ratio and harvesting time of rAAV-shRNA vectors. 
Harvesting time pDG:pAAVshRNA vg/cell ip/cell vp/vg 
48h post TF 
1:1 1.3E+04 7.3E+01 94 
1:3 2.9E+04 9.9E+01 29 
1:9 2.1E+04 6.0E+01 26 
72h post TF 
1:1 1.2E+04 5.2E+01 130 
1:3 1.4E+04 8.3E+01 105 
1:9 9.1E+03 6.0E+01 87 
 
In order to decrease this ratio and, consequently, decrease empty capsids produced, 
different combinations of the referred parameters were tested. Table 1 shows that 
decreasing time of harvest to 48hpt consistently decreased vp/vg ratio. Also, increasing 
the proportion of pAAV in the transfection mix further decreased empty capsid 
production. The final optimized protocol was set at pDG:pAAV = 1:3 and toh = 48hpt for 
the higher ip yield. 
Six rAAV-shRNA vectors, two encoding control scramble shRNA (rAAV-Ctrl1sh, rAAV-
Ctrl2sh) and four gene target shRNA (rAAV-PK1sh, rAAV-MCL1sh, rAAV-PSMA2sh, rAAV-
PSMB4sh) were produced and purified by affinity chromatography. SDS-PAGE followed 
by InstantBlue™ staining revealed high purity levels for all batches (Fig. 2.3).  
The titers obtained after purification (1013 vp/ml; 0.4-1 x 1012 vg/ml; 1010 ip/ml – Table 
2) are within reported ranges[15,25]. Batch quality, in terms of vp/vg/ip, was 
maintained within a small range, suggesting that the optimized protocol overcome 
possible side effects arising from RNAi machinery activation in HEK293T cells. 
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Nevertheless, rAAV-shRNA targeting genetic vulnerabilities showed a tendency to have 
higher vp/vg ratios. 
 
Figure 2.3: Purified rAAV-shRNA vector characterization. Purification of different 
rAAV-shRNA vectors was performed by affinity chromatography using the AVB 
Sepharose high performance resin. Six rAAV-shRNA vectors (two negative scramble 
controls, one positive control, and three rAAV-shRNA vectors targeting three 
different BLBC dependency genes) were obtained. Purity of rAAV-shRNA vectors was 
monitored by SDS-PAGE followed by Instant Blue staining. M: protein standard; VP1, 
VP2, VP3: AAV structural proteins. 
Table 2.2: Purified rAAV-shRNA vector yields. 
rAAV-shRNA vp/mL vg/mL ip/mL 
scramble control 
Ctrl1sh 1.3E+13 1.1E+12 2.1E+10 
Ctrl2sh 4.0E+13 9.3E+11 3.4E+10 
positive control PLK1sh 2.7E+13 3.6E+11 2.0E+10 
BLBC genetic vulnerabilities 
MCL1sh 3.3E+13 4.3E+11 1.7E+10 
PSMA2sh 4.3E+13 1.8E+12 4.3E+10 




3.2 PSMA2 downregulation decreases cell viability and induces apoptosis 
in BLBC cell lines 
3.2.1 rAAV-shRNA target gene knockdown efficiency 
rAAV-shRNA vector transduction efficiency was assessed in two BLBC cell lines – 
HCC1954, a poorly differentiated epithelial cell line derived from a ductal carcinoma 
with no lymph node invasion; and MDA-MB-468, a cell line with epithelial morphology 
derived from a metastatic site. All vectors developed had comparable levels of 
transduction efficiency for each of the cell lines – around 60% for MDA-MB-468 and 
approximately 80% for HCC1954 (Fig. 2.4). 
 
Figure 2.4: Transduction efficiency of rAAV-shRNA viral vectors in BLBC cell lines. Exponentially 
growing MDA-MB-468 and HCC1954 cells were transduced with the indicated viral vectors 
(4.6E+4 vg/cell each). rAAV vector transduction efficiency was monitored 48h post transduction 
by flow cytometry detection of eGFP. Plots show representative data obtained for each cell line. 
Graphics present percentage of transduced cells (mean + SD). 
Target gene knockdown after rAAV-mediated delivery of shRNA to HCC1954 and MDA-
MB-468 cell lines was also assessed. rAAV-PSMA2sh showed a consistent 
downregulation of the target gene in both cell lines, of around 80% knockdown 
efficiency (Fig. 2.5). However, the other rAAV-shRNA vectors assessed showed either no 
detectable gene knockdown (rAAV-MCL1sh), or levels that did not surpass 50% 
knockdown efficiency (rAAV-PLK1sh, rAAV-PSMB4sh). These results significantly differ 
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from the levels obtained after HEK293T transient transfection, likely reflecting 
differences in the shRNA delivery system and target cell. Nevertheless, since the level 
of gene knockdown that translates into an observable phenotype is likely to depend on 
the gene of interest and on the expected outcome, it is difficult to predict if the 
knockdown efficiency observed will have a functional effect. 
 
Figure 2.5: Target gene knockdown efficiency of rAAV-shRNA vectors in BLBC cell lines. 
Exponentially growing A) MDA-MB-468 and B) HCC1954 cells were transduced with the indicated 
viral vectors (4.6E+4 vg/cell each). Twenty-four or forty-eight hours post transduction cells were 
sorted and processed. Total RNA was extracted and the mRNA levels of PLK1, MCL1, PSMA2 and 
PSMB4 were determined by qRT-PCR. mRNA levels were normalized against housekeeping 
HPRT1 and RPL22 genes within the same sample and are shown as fold change relative to the 
respective levels in cells transduced with rAAV-Ctrl1sh vector (mean + SD) of three independent 
experiments. 
3.2.2 In vitro biological activity 
To evaluate whether downregulation of the target genes has an impact in BLBC 
tumorigenic potential, the effects of their knockdown were evaluated in terms of impact 
on cell viability and apoptosis induction in HCC1954 and MDA-MB-468 cell lines. In 
MDA-MB-468, a generalized decrease in viability of around 30% was observed after 
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rAAV-mediated delivery of PLK1sh, PSMA2sh and PSMB4sh, when compared to cells 
transduced with scramble control (Fig. 2.6 – A). 
These results indicate that even a moderate level of gene knockdown may deliver the 
desired effect. Therefore, further optimization of the shRNA sequences for the genetic 
 
Figure 2.6: Functional effects of rAAV-shRNA vectors in BLBC cell lines. Exponentially growing 
MDA-MB-468 cells were transduced with the indicated viral vectors (4.6E+4 vg/cell each). 
Twenty-four and forty-eight hours thereafter, transduced cells were sorted and further cultured. 
A) Cell viability was measured using Presto Blue fluorometric assay at different culture time 
points. Cellular viability was calculated as a percentage relative to cells transduced with rAAV-
Ctrl1sh vector. Shown is mean percent viability of transduced cells at 72h post-transduction + SD 
from 3 independent experiments. B) Sorted cells were seeded, and apoptosis determined by 
FLICA apoptosis kit by flow cytometry. The graphics show average cell apoptosis (+ SD) of 3 
independent experiments, at day 5 post-transduction. *, p <0.05 vs. values in cells transduced 
with scramble control (Ctrl1sh). Statistical significance was determined using the two-tailed 
Student´s t-test. 
vulnerabilities here exploited could be warranted, in an attempt to increase gene 
knockdown to potentiate the functional effect. In terms of apoptosis induction in these 
cells, a statistically significant increase was achieved with rAAV-PSMA2sh, with up to 2-
fold increase in the percentage of apoptotic cells compared with the scramble control 
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(Fig. 2.6 – B). This is in line with the displayed knockdown efficiency of the referred 
vector. In HCC1954 cells, significant decrease of cell viability was observed only for 
rAAV-PLK1sh viral vector, and there was no significant effect on apoptosis induction by 
any of the viral vectors tested in these cells (data not shown). The different biologic 
activities of the viral vectors between MDA-MB-468 and HCC1954 might be due to their 
different molecular signatures and oncogenic status[26]. 
3.3 Effect of rAAV-PSMA2sh intratumoral injections BLBC mouse 
xenografts 
To evaluate whether the predicted genetic vulnerabilities can be harnessed for BC 
therapy using the developed technology, we assessed whether PSMA2 knockdown 
could suppress tumor growth in vivo using BLBC mouse xenografts. When tumors were 
circa 100 mm3, mice were treated with rAAV-PSMA2sh, rAAV-PLK1sh, rAAV-Ctrl1sh or 
PBS, using two vector dosages, by intratumoral injections. Tumor progression was 
monitored every 3 days by measuring the tumor volume in each condition. 
As an aggressive tumor model, growth of tumor mass was rapid, especially for control 
groups treated with PBS or with the scramble controls, in both vector dosages tested 
(Fig. 2.7). 
  
Figure 2.7: Effect of rAAV-shRNA vectors on tumor growth rate of BLBC xenografts. A) and B) 
Fold change in tumor volume progression in mice injected with 2x109 or 2x108 
vg/tumor/injection, respectively. Data are mean ± SEM. The statistical difference between the 




However, mice treated with rAAV-PSMA2 showed a consistent reduction in tumor 
growth over time, apparent after day 13 of treatment (Fig. 2.7). Interestingly, for rAAV-
PLK1sh, a reduction in tumor growth is only apparent for the highest dose, possibly 
reflecting the lower gene downregulation achieved with this construct and consequent 
lower impact on cell viability. 
No significant differences were observed in the gain or loss of mice weight. Moreover, 
no major macroscopic alterations were observed in the liver of mice treated with either 
vector, suggesting that the rAAV2-shRNA viral injections did not prompt significant side-
effects nor hepatotoxicity. 
The impact of rAAV-shRNA intratumoral injections on tumor growth of BLBC mouse 
xenografts was analyzed independently for a separate group of mice. These mice 
suffered from a bacterial infection and had to be subjected to antibiotic treatment over 
the course of the experiment. Here, both rAAV-PSMA2 and scramble control led to a 
persistent decrease in tumor growth over time (Fig. 2.8).  
 
Figure 2.8: Effect of rAAV-shRNA vectors on tumor growth rate of BLBC xenografts. 
Fold change in tumor volume of mice injected with 2x109 VG/tumor/injection. Data 
are mean ± SEM. The statistical difference between the groups was determined by 
Two-way ANOVA using the GraphPad™ 6 (Prism®) software (***p<0.001, **p<0.01). 
Previous studies had already reported that some of the antibiotics commonly used in 
cell culture can significantly alter gene expression of human liver[27] and keratinocyte 
cell lines[28]. Others have even proposed the use of antibiotics for anticancer therapy, 
including breast cancer[29]. Therefore, the antibiotic treatment appears to be inducing 
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slower tumor growth over time and, consequently, affecting tumor’s response to the 
treatment in the model used. 
Previous reports showed that different BLBC cell lines underwent caspase-dependent 
apoptosis after infection with AAV2. This was correlated with differential expression of 
non-structural proteins in these cell lines, and was concomitant with increased 
expression of proliferation markers c-Myc and Ki-67[30]. Since we are not working with 
wtAAV2, the rAAV2 vectors used do not express non-structural proteins, therefore a 
different mechanism is responsible for this effect. Additionally, no differences were 
found in the expression of proliferation (Fig. 2.9 – A) or apoptosis (Fig. 2.9 – B) markers 
between the different rAAV2-shRNA viral vectors tested. The mechanisms at play here 
could possibly be a result of a synergistic effect of the antibiotics and unspecific toxicity 
related with the rAAV capsid, which was unaltered between all rAAV variants produced. 
 
Figure 2.9: Evaluation of BLBC xenografts proliferation and apoptotic indexes over the course 
of the treatment. Immunohistochemical analysis of tumor samples derived from BLBC 
xenografts after treatment at the referred time points. Data are mean ± SEM. 
4. DISCUSSION 
This study evaluates the potential of rAAV-mediated shRNA delivery for the 
downregulation of genes necessary for the survival of BLBC cells. Our results indicate 
that standard upstream methods for rAAV production, based on transient transfection 
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of HEK293T cells, lead to high empty capsid titer in the final formulation of rAAV vectors 
encoding shRNA constructs. We showed that by increasing the transgene/packaging 
plasmid ratio in the transfection mix, which likely reduces the probability of empty 
capsid formation, the vp/vg ratio was improved and ip titers were slightly increased. 
Additionally, the combination of the optimal ratio with a decrease in the time of harvest 
to 48hpt, further lowered empty viral vector titers. A lower vp/vg ratio is instrumental 
for the successful employment of gene therapy approaches as empty capsids will 
decrease therapy potency and increase immune responses to capsid proteins. 
The success of anticancer therapeutics using the referred approach, or even the correct 
interrogation as to possible clinical utility, is dependent on the development of suitable 
delivery systems for safe and efficient introduction of shRNA molecules into tumor cells. 
AAV was shown to be a viable option, as rAAV vectors are among the most promising 
gene therapy products developed to date. After numerous successful applications in the 
treatment of monogenic diseases by gene replacement[31–33], AAV arsenal has been 
broadened to comprise several anti-cancer therapies[5] and different clinical modalities 
that include RNAi and genome engineering strategies such as CRISPR/Cas9[34]. The low 
transgene loading capacity, often impairing rAAV-mediated gene therapy, is not an issue 
with these approaches, and makes such small DNA-encoded RNA molecules ideal 
transgenes for these vectors. 
Also pivotal for successful therapy is maximizing vector production while maintaining 
batch consistency. However, reaching high titers during upstream processing entails 
high expression of the transgene in producer cells. While few concerns arise when 
dealing with inert gene products, that generally set the gold standard for vector titer 
production, the biological activity of cytotoxic transgenes for cancer therapy on 
producer cell lines may impact its protein synthesis capacity, metabolism and viability, 
or impact vector assembly itself[35]. Concerning shRNA applications, the activation of 
the RNAi machinery in HEK293T cells during rAAV production, combined with the extra 
burden of producing heterologous proteins, decreased cell viability over time (which 
was lower at 72hpt – data not shown), and impaired the quality of vector preparations. 
Our findings add to a growing body of literature on strategies to circumvent such side 
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effects. These include the addition of extra proteins and extensive genetic manipulation 
of the transgene[35], addition of aptamers[36], the inhibition of transgene expression 
on producer cells via siRNA or by activation of toxic genes only through the excision of 
spacer DNA by Cre-recombinase delivered via a second vector[37]. The simpler strategy 
applied here is flexible enough to allow transgene-dependent optimization if required, 
while reaching yields comparable to current rAAV production platforms[23,25]. 
To assess the potential of this strategy to be used as a BLBC therapeutic approach, we 
transduced BLBC cell lines with rAAV vectors expressing shRNA against previously 
identified genetic vulnerabilities of this BC subtype. rAAV-PSMA2 transduction caused a 
specific and potent decrease in PSMA2 expression in both cell lines tested, as compared 
to cells transduced with rAAV carrying a scramble shRNA. The reduced expression of 
PSMA2 resulted in a decrease of viability and increased apoptosis in MDA-MB-468 cells. 
Furthermore, rAAV2-PSMA2 intratumoral injections in BLBC mouse xenografts led to a 
consistent decrease in tumor growth over time, when compared to PBS or scramble 
controls. These results are consistent with Petrocca et al, which indicated that proteins 
from the proteasome machinery are fundamental for BLBC cell viability[9], and suggest 
that this could be a promising therapeutic vector against this type of cancer. 
Although previously conducted clinical trials have led to regulatory approval of 
proteasome inhibitors for the treatment of various diseases, including multiple 
myeloma and mantle-cell lymphoma, acquired resistance mechanisms commonly arise 
and undermine effectiveness of the therapy[38]. Also, preclinical efficacy of these 
inhibitors for solid tumors could not be translated into the clinic, indicating the 
importance for development of suitable delivery platforms, as even the most potent 
therapeutic can fail in the clinic due to inefficient delivery[38]. 
Therapeutic posttranscriptional gene silencing via shRNA can target each gene’s mRNA, 
as well as the considered undruggable genome[10]. In contrast to proteasome 
inhibitors, this approach offers the possibility to evolve in a sequence specific manner, 
which could overcome resistance mechanisms arising from genetic mutations. Also, it 
possesses superior advantages over other strategies with proven clinical efficacy, 
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including small-molecule inhibitors, such as imatinib for the treatment of chronic 
myeloid leukemia[39], and monoclonal antibodies, such as Trastuzumab for HER2-
positive early breast cancer[40]. Small-molecule inhibitors have low degree of specificity 
when it comes to target modulation, which can lead to adverse side effects, and often 
do not restrict the entire function of a protein, leading to inefficient anti-oncogenic 
effects[41–44]. On the other hand, monoclonal antibodies are restricted to membrane 
or circulating proteins[42]. 
Taken together, this study showed evidence that further optimization of standard 
upstream rAAV production platforms, based on transient transfection of HEK293T cells, 
has the potential to overcome transgene cytotoxicity in vector-producing cells. 
Moreover, our results provide proof-of-concept that rAAV-mediated delivery of shRNA 
targeting BLBC dependency genes can be a promising approach for the treatment of this 
disease. The strategy here developed represents an improvement on traditional 
employment of suicide gene therapy for cancer. Classical suicide gene approaches will 
kill cells indiscriminately and rely solely on targeted delivery for specificity. Directing 
therapy to cancer specific dependency genes will confer a higher degree of specificity 
and safety to the treatment. Nevertheless, it still maintains the possibility to be 
combined with capsid engineering approaches for an additional layer of 
specificity[45,46]. This strategy might also be suitable for treatment of other 
malignancies. The shRNA can be customized to any tumor dependency and tailored to 
different subtypes or different tumors. Also, a combination of rAAV batches encoding 
different transgenes can be used to decrease the emergence of tumor resistance. 
Finally, given the indication for therapeutic potential of these targets, evaluation of 
clinical efficacy in more relevant models of tumorigenesis should be warranted. 
Although a modest decrease in tumor progression was observed in BLBC mouse 
xenograft models, these mice are immunocompromised and thus do not portray the 
immunogenicity of the therapy developed. It is now established that several anticancer 
therapeutics that induce apoptosis in tumor cells can trigger an antigen-specific immune 
response[47]. This, in turn, reactivates the immune system against tumor cells, 
enhancing therapeutic response. Consequently, the assessment of anticancer drugs is 
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now shifting towards the use of immunocompetent mice for proper evaluation of the 
therapeutic outcome[47]. With the development of in vitro human models that 
incorporate immune cells, testing promising leads in a human setting may also be 
possible[48].  
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ABSTRACT 
Basal-like breast cancer (BLBC) has currently no validated surface biomarkers that could 
direct targeted therapies. Thus, the only therapeutic option for these patients is still 
chemotherapy, which entails toxic side-effects. Here, we used a peptide library 
displayed on AAV vectors to select for AAV capsids with restricted tropism and that 
could mediate BLBC-specific transduction. By following a directed evolution approach 
through sequential infection rounds in BLBC cell lines, we were able to select a single 
peptide motif enrich within the library. Overall tropism for this AAV variant was 
maintained for all the cancer cell lines tested, spanning different subtypes of breast and 
lung cancer, as well as a fibrosarcoma cell line. Transduction efficiency of the selected 
variant was decreased for embryonic kidney and hepatic cell lines when compared to 
wild-type (wt) AAV2 capsids. On the other hand, transduction efficiency was increased 
for human dermal fibroblasts and normal mammary epithelial cells. Therefore, we were 
successful in selecting an AAV variant (AAV-X7) with altered tropism when compared to 
vectors carrying the wild-type AAV2 capsid. However, this variant presents limited 
potential for BLBC targeted therapy since it still is able to infect normal breast epithelial 
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1. INTRODUCTION 
Breast cancer (BC) is an heterogeneous disease in terms of molecular phenotypes and 
disease outcomes. Over the years, extensive research has been directed at dividing BC 
into subgroups that could instruct clinical decisions. Both transcriptomic and genomic 
studies have classified BC into “intrinsic” subtypes which are mostly defined by the 
expression of three biomarkers: endocrine receptors for oestrogen (ER) and 
progesterone (PR), and altered expression of HER2[1,2]. ER+ BC (Luminal A/B subtypes) 
are the most common and present a good prognosis when treated with endocrine 
therapies, although relapses still occur[3]. The HER2-enriched subgroup has also seen 
its prognosis drastically improved with the development of targeted therapies for this 
receptor[4]. Basal-like breast cancer (BLBC), on the other hand, currently has no 
validated biomarkers, other than absent or low expression of ER, PR and HER2. In fact, 
more than 90% of BLBC are negative for all three receptors; thus, these do not respond 
to available targeted therapies. Therefore, there is an urgent need for identification of 
biomarkers that could help target BLBC and improve prognosis[5]. 
AAV vectors´ extensive preclinical and clinical studies have highlighted their safe and 
efficacious profile for gene therapy[6]. Moreover, the increasing understanding of AAV 
capsid structure has facilitated the rational design of AAV variants with clinical 
potential[7,8]. On the other hand, progress in AAV capsid library development has 
supported directed evolution approaches[9,10]. Here, wild-type (wt) capsid encoding 
genes are mutated using different approaches, generating large peptide libraries 
displayed in AAV vectors[11]. These are then subjected to selective pressure to isolate 
novel AAV variants with enhanced properties for in vivo gene delivery, such as increased 
infection efficiency and lower immunogenicity profiles[11]. 
Since there are no known cellular receptors available for BLBC targeting, we used a 
directed evolution approach to select for an AAV variant with increased tropism and 
transduction efficiency towards this BC subtype. For this, we used a random peptide 
library displayed on AAV2 vectors (AAV library)[12]. The peptides were inserted at the 
site of attachment to the viral receptors, at the surface of the vector capsid, thereby 
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decreasing AAV2 vectors´ endogenous tropism[12]. After multiple rounds of infection 
of the AAV library on BLBC cell lines a single AAV variant was selected, which enabled 
efficient transduction of BLBC cell lines. Nevertheless, a broader analysis of its tropism 
revealed that it was still able to infect cells from other tissues, thus limiting its potential 
for BLBC directed therapy. 
2. MATERIALS AND METHODS 
2.1 Cell culture 
HEK293T, AAV293 and HT1080, MCF7 and HepG2 cell lines were cultured in high glucose 
(4.5 g/L) DMEM supplemented with 10% (v/v) fetal bovine serum (FBS). Basal breast 
cancer (BLBC) cell lines HCC1187, HCC1954, HCC1806, HCC1937, MDA-MB-231, MDA-
MB-468, were cultured in RPMI 1640 medium supplemented with 10% (v/v) FBS, 6 mM 
HEPES and 5 µM 2-Mercaptoethanol. H1650 cell line was cultured in RPMI 1640 medium 
supplemented with 10% (v/v) FBS. Human Dermal Fibroblasts (HDF), from Innoprot, 
were cultured in IMDM supplemented with 10% (v/v) FBS. Primary breast epithelial cells 
were cultured in WIT-P™ Culture Medium (Stemgent). Media and cell culture reagents 
were from Gibco Life Technologies, unless otherwise specified. Cells were incubated at 
37 °C in a humidified atmosphere with 5% CO2 in air. 
2.2 AAV peptide library biopanning 
PBEC and BCLC cell lines were infected with an AAV display peptide library kindly 
supplied by Prof. Martin Trepel’s group, University Medical Center Hamburg-
Eppendorf[12]. After 8hrs cells were washed with PBS followed by incubation with wild-
type Ad5 at an MOI of 100pfu/cell in serum free media. After 1h incubation, cell´s 
culture media was added, and cell were further cultured for 72hrs. Replicated AAV 
particles were harvested from supernatant and from cell, concentrated using vivaspin 
columns, and used for the subsequent rounds of infection. wtAd5 harvested from each 
selection round was inactivated by incubating the lysate and supernatant for 45 min at 
55ºC. This biopanning cycle was repeated 3 to 5 times. 
Engineering AAV2 vector tropism through in vitro directed evolution 
77 
2.3 PCR-amplification and sequencing of insert sequences 
Replicated AAV particles recovered after selected round were recovered, incubated for 
10 min at 90°C to inactivate wtAd5 and release the AAV genomes from the particles, 
and insert sequences were amplified using primers 5’-CCCGTGGCTACGGAGC-3’ and 5’-
TGACATCTGCGGTGGCC-3’, as previously described[12]. PCR products were analyzed by 
gel electrophoresis and purified using PCR purification Kit (Quiagen cat#28106). A 
ligantion reaction using T4 DNA ligase was performed and the product was analyzed by 
gel electrophoresis. Bands ranging from 800 and 1500 bp were cut from the gel and 
purified with the Peqlab gel extraction kit, cloned into pJet2.1 vector (Fermentas cat# 
K1232), and transformed using electrocompetent DH5alfa cells. Randomly selected 
clones were sequenced. 
2.4 Phage library biopanning 
Selection of peptides was performed using Ph.D.-12™ Phage Display Peptide Library 
(NEB #E8111L). Briefly, primary breast epithelial cells were used to deplete the phage 
library of non-specific binders. The cells were washed twice with PBS and blocked with 
PBS containing 1% bovine serum albumin (BSA) at 37°C for 1 h. Approximately, 1x1011 
pfu phages were added and mixed gently for 1 h at 37˚C. During this time, target cells 
were pre-washed and blocked. The supernatant containing unbound phages was 
transferred to blocked target cells and incubated for 2hrs on at 37˚C. After four intensive 
washes of cells with PBS containing 0.2% Tween-20, bound phages were eluted from 
cells by incubation with 0.2 M glycine–HCl, pH 2.2 for 15 min. The eluate was 
immediately neutralized by the addition of 200 µl of 1 M Tris–HCl buffer at pH 9.1. 
Selected phages were amplified in E. coli for next rounds. At the third round of 
biopanning clones were sequenced by colony PCR.  
2.5 Production and purification of AAV vectors 
Selected capsid modified AAV vectors were produced and purified as described in 
Chapter II – section 2.3. 
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2.6 In vitro vector characterization 
All cells were transduced using the capsid modified AAV vectors as described in Chapter 
II – section 2.5. Percentage of transduced cells was analyzed by identification of GFP+ 
cells by flow cytometry. 
3. RESULTS 
3.1 Selection of peptides targeting human basal-like breast cancer cells 
Using a random peptide library displayed on AAV vectors (AAV library) previously 
developed[12], a directed evolution approach was followed using different strategies, 
as depicted in Fig. 3.1. 
 
Figure 3.1: Schematic representation of the different strategies followed for in vitro directed 
evolution AAV library on BLBC cells. Images were adapted from Kotterman et al., Nat Rev Gen 
(2014) and New England Biolab® protocol. 
To decrease these vectors ability to infect normal mammary tissue and restrict AAV2 
tropism, the AAV library was subjected to an initial depletion step, using primary breast 
epithelial cells (PBEC). All the AAV variants unable to bind and internalize were 
recovered in the supernatant. Following the depletion step, to select for AAV capsids 
with high transduction efficiency and selective tropism toward BLBC, cell lines from the 
referred BC subtype were infected with the depleted supernatant. 
HCC1187 cell line was chosen for the initial screenings due to its high tumorigenic 
phenotype. After AAV library infection, these cells were superinfected with Ad5 for 
amplification of internalized clones. Amplified clones were recovered and used in 
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subsequent rounds of infection to select and enrich for AAV variants with ability to 
efficiently bind, enter and replicate in BLBC cell lines. One peptide motif was enriched 
upon screening the AAV library. Sequencing of the DNA region coding for the 7-peptide 
motif inserted in the AAV library of the selected clones was done after three and five 
selection rounds. DNA sequencing revealed a 15% enrichment of one peptide motif only 
after five rounds of biopanning using the first strategy. The enriched peptide motif was 
RDGERPG (X7). 
To avoid selection of an AAV variant specific for the HCC1187 cell line and increase the 
chances of finding a variant that would allow broad infection of multiple BLBC, a second 
strategy was followed, consisting of using different BLBC cell lines for the biopanning 
selection steps (Fig. 3.1). Unfortunately, this approach did not result in enrichment of 
AAV variants. As an alternative, a screening using a phage-display peptide library was 
performed with the HCC1187 cell line, which resulted in enrichment in a single peptide 
motif - PNLHAWVP (pdl). 
The two peptide motifs identified were cloned into AAV2 rep-cap plasmid and used for 
the production of AAV vectors displaying the selected peptides: AAV-X7 and AAV-pdl, 
respectively. As a positive control, an AAV variant containing the wild-type AAV2 capsid 
was also produced and used for comparison in further studies (wtAAV2). 
3.2 Tropism evaluation 
To validate the targeting potential of the selected peptide for AAV-mediated gene 
transfer, BLBC cell lines were transduced with the developed AAV variants, and its 
transduction efficiency was compared to that of AAV vectors carrying the wt capid 
(wtAAV2). The AAV vectors produced carried eGFP reporter gene to facilitate 
transduction monitoring via flow cytometry. Tropism was evaluated by analyzing the 
transduction efficiency of both control (wtAAV2) and capsid modified AAV vectors (AAV-
X7 and AAV-pdl) in different cell lines. The AAV variant containing the pdl peptide motif 
(AAV-pdl) showed decreased transduction efficiency in all cell types tested (data not 
shown). This may indicate that the insertion of the peptide motif arising from the phage 
library caused a disruption in the AAV2 capsid, impairing its infectivity. 
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Regarding the AAV-X7 variant, transduction efficiency in all BLBC cell lines tested was 
maintained when compared to wtAAV2 (Fig. 3.2). To evaluate cell-type specificity, 
transduction efficiency was also evaluated for normal breast epithelial control cells, as 
well as for cells from irrelevant tissues. Similarly to BLBC cells, the AAV-X7 vector 
transduced the cancer cell lines MCF7 (luminal A breast cancer), HT1080 (fibrosarcoma) 
and H1650 (lung adenocarcinoma) at levels similar to those of wild-type vector (Fig. 3.2). 
 
Figure 3.2: Transduction efficiency and tropism evaluation of AAV variant expressing the 
selected peptide motif. The indicated cells were transduced with control wild type AAV2 
(wtAAV2) or capsid-modified AAV-X7 vectors at 4.57x103 VG/cell. Transduction efficiency 
monitored 48h thereafter by detection of GFP+ cells by flow cytometry. Transduction efficiency 
of AAV-X7 was calculated relative to transduction efficiency of cells transduced with wtAAV2 
vector. Plots show fold change in percentage transduced cells (mean + SD) of several 
independent experiments, each done in duplicate. *, p <0.05. Statistical significance was 
determined using the two-tailed Student´s t-test. 
Proof of tropism alteration arose when hepatic (HepG2) and embryonic kidney 
(HEK293T and AAV293) cell lines were tested. In these cells, transduction efficiency of 
AAV-X7 was reduced by 40% to 80% depending on the cell line (Fig. 3.2). On the other 
hand, AAV-X7 vector showed increased transduction efficiency towards normal breast 
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epithelial cells (2-fold) and human dermal fibroblasts (1.4-fold) when compared to the 
wild-type control vector (Fig. 3.2); thus, impairing its potential for BLBC targeting. 
4. DISCUSSION 
Several studies have shown the feasibility of engineering AAV capsid for binding to 
alternative receptors. The development of systematic tools to generate vectors 
targeting any cell-type of interest, such as peptide libraries displayed on AAV vectors, 
can facilitate the process of finding variants of interest[12]. 
Since there are no known targets for basal-like breast cancer (BLBC), with the goal of 
finding AAV variants with improved efficiency for BLBC cell-directed gene transfer, the 
AAV library developed by Muller et al. was panned on BLBC cell lines. Several strategies 
were followed using sequential rounds of panning i) on the same cell line, or ii) using 
multiple BLBC cell lines. Although the second strategy would increase the chances of 
finding AAV variants that target BLBC, independently of their intrinsic heterogeneity, it 
did not support enrichment in any particular peptide motif. This may indicate that the 
cell lines used are too diverse, decreasing the probability of finding a common receptor 
target. Such heterogeneity has also been reported for BLBC patients[5]. 
Sequential rounds of infection using the same cell line resulted in 15% enrichment in a 
single peptide motif – RDGERPG. The targeting properties of the AAV variant 
incorporating the selected peptide (AAV-X7) were evaluated in vitro, by comparing its 
transduction efficiency with that of the wtAAV2 capsid in cell lines from different 
tissues. Transduction efficiency of AAV-X7 for BLBC was maintained when compared to 
the wtAAV2 capsid. However, AAV-X7 was still effective in transducing normal breast 
epithelium and human dermal fibroblasts. This suggests that there will be unspecific 
targeting of non-relevant tissues in vivo, thus impairing its use as a therapy for BLBC. 
When compared to the wtAAV2 capsid, AAV-X7 presented decreased transduction 
efficiency for human embryonic kidney and hepatocellular carcinoma cell lines. These 
represent cell lines from different tissue-of-origin and cellular morphology (epithelial vs 
mesenchymal); thus, it is unclear how restricted is the tropism of the developed variant. 
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Further tests are required for proper characterization of the selected AAV and discovery 
of the targeted receptor. 
The incorporation of peptides selected from different platforms, namely phage display, 
within AAV capsids has been successful. It presents important advantages over 
bispecific conjugates for systemic treatment due to the possible instability of the vector-
conjugate complex and immunogenicity of the adaptor[12]. The development of phage 
display peptide libraries increased power and throughput of screening methods. These 
are efficient tools for fast selection of ligands for different molecular targets and have 
been successfully screened for binding specificity to endothelial cells in vitro[13], on 
tumor tissue sections[14] and in vivo[15,16]. Here, we used a phage display peptide 
library as an alternative approach to identify relevant BLBC-binding peptides. After 
three rounds of biopanning on a BLBC cell line, we identified a single peptide motif 
enriched in the clones sequenced. The sequence – PNLHAWVP – presented high 
homology to a peptide ligand for breast ductal carcinoma, previously identified by Lu et 
al., in a similar biopanning campaign[17]. This highlights the power and reproducibility 
of the screening technology; nevertheless, it may indicate that the tropism of the 
engineered AAV capsid will not be restricted to BLBC. AAV vectors displaying the 
selected peptide presented low transduction efficiency in all cell lines tested. Upon 
incorporation into the viral capsid, the peptide conformation may be altered, or it may 
interfere with the proper assembly of the viral capsids. Moreover, since these peptides 
are selected for binding and not necessarily entry into the target cell, if the target 
receptor does not support internalization of the ligand, the developed vectors will not 
be suitable for gene transfer[12]. Further analysis are required to understand what is 
impairing transduction for AAV-pdl. 
Lastly, additional strategies are currently ongoing to select recombinant virus with 
specific tropism towards BLBC cells. These include the use of a more stringent depletion 
strategy (by increasing the number of infection cycles using primary breast epithelial 
cells), prior to biopanning in BLBC cell lines. 
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Breast cancer cell lines have been essential for elucidating BC biology and finding novel 
therapeutics[18,19]. Also, several studies have reported that the heterogeneity of gene 
expression and genomic aberration profiles is maintained to a certain extent within the 
BC cell lines currently available[20,21]. Nevertheless, the routine culturing of these cells 
under non-physiological culture conditions may impair biological studies. Therefore, 
biopanning for peptide motifs with restricted tropism towards BLBC using cellular 
models that more accurately reflect the biology of this subtype can be pursued. These 
include 3D cellular models where the tumor architecture, and thus relevant cell-cell 
interactions and surface receptors, are maintained. This is expected to increase the 
chances of finding a peptide motif suitable to develop an AAV-based therapy against 
breast cancer.  
Moreover, biopanning using in vivo animal models is also an alternative. This allows for 
the simultaneous selection of relevant peptide motifs, while avoiding peptides that bind 
to the other tissues. It is important to note that selection would be done in a murine 
environment, thus differences compared with human tissues may arise.   
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ABSTRACT 
The tumour microenvironment (TME) shapes disease progression and influences 
therapeutic response. Most aggressive solid tumours have high levels of myeloid cell 
infiltration, namely tumour associated macrophages (TAM). Recapitulation of the 
interaction between the different cellular players of the TME, along with the 
extracellular matrix (ECM), is critical for understanding the mechanisms underlying 
disease progression. This particularly holds true for prediction of therapeutic 
response(s) to standard therapies and interrogation of efficacy of TME-targeting agents. 
In this work, we explored a culture platform based on alginate microencapsulation and 
stirred culture systems to develop the 3D-3-culture, which entails the co-culture of 
tumour cell spheroids of non-small cell lung carcinoma (NSCLC), cancer associated 
fibroblasts (CAF) and monocytes. We demonstrate that the 3D-3-culture recreates an 
invasive and immunosuppressive TME, with accumulation of cytokines/chemokines 
(IL4, IL10, IL13, CCL22, CCL24, CXCL1), ECM elements (collagen type I, IV and fibronectin) 
and matrix metalloproteinases (MMP1/9), supporting cell migration and promoting cell-
cell interactions within the alginate microcapsules. Importantly, we show that both the 
monocytic cell line THP-1 and monocytes from healthy donors infiltrate the tumour 
tissue and transpolarize into an M2-like macrophage phenotype expressing CD68, 
CD163 and CD206, resembling the TAM phenotype in NSCLC. The 3D-3-cultures were 
challenged with chemo- and immunotherapeutic agents and the response to therapy 
was assessed in each cellular component. Specifically, the macrophage phenotype was 
modulated upon treatment with the CSF1R inhibitor BLZ945, resulting in a decrease of 
the M2-like macrophages. In conclusion, the crosstalk between the ECM and tumour, 
stroma and immune cells in microencapsulated 3D-3-cultures promotes the activation 
of monocytes into TAM, mimicking aggressive tumour stages. The 3D-3-culture 
constitutes a novel tool to study tumour-immune interaction and macrophage plasticity 
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1. INTRODUCTION 
Cell-cell and cell-matrix interactions, involving tumour, stromal and immune cells, are 
critical in all steps of tumour development and have been extensively studied in recent 
years. Moreover, reports on their impact on patient prognosis and therapeutic response 
are also increasing[1,2]. Immune checkpoint blockade and adoptive T-cell therapy 
approaches have introduced immunotherapies as viable clinical modalities, alongside 
chemotherapeutics and targeted agents[3]. However, there are still considerable 
challenges in understanding why in some tumour types immunotherapy has no clinical 
effect and why certain patients fail to respond to the treatment[4–6]. Undeniably, there 
is a need to understand the mechanistic effects of a therapy within the immune 
regulatory context of a given tumour microenvironment (TME), leading to more 
effective approaches, and harnessing the full potential of the TME as a therapeutic 
target[7]. 
Non-small cell lung cancer (NSCLC), one of the most lethal malignant diseases, is 
typically associated with extensive myeloid cell infiltration[8,9]. Infiltrating myeloid cells 
are key mediators of immune suppression, neovascularization, invasiveness, metastasis 
and poor response to therapy. Consequently, those cells constitute an important target 
for the development of novel immunotherapies[10,11]. In most solid tumours, including 
NSCLC, macrophages constitute the main myeloid infiltrate, representing up to 50 % of 
the tumour mass[12,13]. Circulating monocytes are recruited to the tumour tissue and 
can be transpolarized towards the M1-like or M2-like phenotype. Tumour associated 
macrophages (TAM) have been linked with the M2-like phenotype, exerting tumour-
promoting effects such as induction of proliferation, angiogenesis, ECM remodelling and 
evasion from adaptive immunity such as secretion of arginase 1[14]. In contrast, M1 
macrophages have a tumour suppressive effect[13]. The presence of TAM infiltrate 
affects tumour response to standard-of-care drug treatments[15] and were shown to 
be an important therapeutic target. For instance, by inhibiting the colony stimulating 
factor 1 receptor (CSF-1R), which is the main route of activation and survival of 
monocytes, the tumour progression both in murine models as well as in patients was 
controlled, resulting in an extended survival rate[16–18]. Most of the knowledge on 
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TAM infiltrate has been derived from histological examination of patient samples in 
retrospective cohort studies where myeloid cells have been identified by a few 
immunohistochemistry markers, providing no information about the TAM function per 
se[10,19]. Therefore, technological developments are urgently needed including the 
development of in vitro models that can recapitulate tumour-immune interactions in a 
TME relevant context, while allowing rapid and thorough characterization of the 
immune compartment, to screen and functionally assess novel therapeutics in high 
throughput platforms[4]. 
Preclinical models consist mainly of human tumour-derived cell lines, propagated in 2D 
culture or used in the implementation of mouse xenografts, and on genetically 
engineered mouse models (GEMM) of human tumorigenesis[20]. Although 2D cultures 
provided important insights into potential anticancer agents at early stages of drug 
development, they cannot recapitulate the gradients of nutrients, oxygen and drug 
penetration occurring in vivo and do not account for key TME triggers[21,22]. Human 
cell line-derived xenografts differ considerably from primary human tumours in terms 
of proliferative capacity and TME[23,24]. In addition, the immune system is often 
compromised, thus these models cannot reliable support immunomodulatory drug 
development[24]. Immune-competent and genetically engineered mouse models 
(GEMM) overcome some of the drawbacks, as they allow for the presence of the 
complete immune system. However, those models are still based on murine stromal 
and immune components[24,25]. For most aggressive cancers, including several lung 
cancers, drug candidates arising from 2D cell-line screens and mouse xenograft models 
present poor clinical translation[22]. The discrepancy between these models and the 
human situation in key physiological features, such as human tumour-stroma, tumour-
immune cell interactions and gradients of drug penetration in the tissue have a 
significant impact on the therapeutic response[22]. Therefore, the combination of in 
vivo cell models with advanced in vitro cell models offers a complementary approach to 
study the mechanisms underlying tumour development in the context of the TME. 3D 
cellular models have the potential to advance drug discovery and streamline 
progression of novel candidates through drug discovery pipelines. The need for more 
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predictive drug assays triggered advances in cell culture techniques that led to the 
appearance of complex in vitro models[21]. Tumour spheroids offer an alternative to 
high throughput monolayer-based assays and are complementary to mouse 
models[20]. Several methods for spheroid production are currently available, such as 
low adhesion plates, the hanging drop method,  cell-seeded matrices and scaffolds, 
micropatterning and agitation based methods[26]. Tumour spheroids can mimic drug 
response of primary human tumours and have proven useful in the study of tumour 
physiology, such as metabolic and chemical gradients, hypoxic environment and cell-
cell and cell-matrix interactions[20,21,27,28]. Heterotypic cellular models have been 
successfully employed in unravelling new aspects of cancer biology[23,26]. Most 
heterotypic models include stromal cells, such as cancer-associated fibroblasts (CAF), 
which have been shown to enhance the inflammatory environment, promote tumour 
progression and lead to drug resistance[29]. Reports of in vitro models of immune 
interaction with tumours from diverse pathologies are mostly focused on the tumour 
phenotype and its modulation by the macrophages via secreted factors[30–33]. In lung 
cancer, it has been reported that the presence of macrophages promotes a metastatic 
phenotype due to the presence of MMP-1 and VEGF[34]. However, the dynamic 
interaction between both cell types and the effect of TME heterogeneity on the 
response to chemotherapeutic or immune-targeted agents has scarcely been assessed 
in these types of models. Most studies focusing on macrophage and tumour interaction 
in response to therapy still rely on mouse models using in vivo imaging tools that, 
although capable deciphering tumour architecture and cell interaction networks, are 
technically demanding and not compatible with high throughput screening[19,35] 
In the present work, we establish a 3D cell model (3D-3-culture), enclosing three cellular 
components: NSCLC cells as tumour spheroids, CAF and monocytes. The model is based 
on the alginate microencapsulation strategy previously described by our group, which 
allows direct interaction between different cell types and is compatible with continuous 
monitoring and functional assessment in long-term culture using stirred systems[26,29]. 
Here we demonstrate the recruitment of human monocytes into tumour tissue and 
their polarization into a M2-like phenotype without directed differentiation by the 
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addition of exogenous cytokines, thus recreating the TAM phenotype in vitro. 
Moreover, the TME response to therapy is assessed, depicting the differences in each 
cellular compartment upon treatment and demonstrating that the macrophage 
phenotype can be modulated in response to chemo- and immunotherapy. 
2. MATERIAL AND METHODS 
2.1 Cell lines 
The NSCLC cell line NCI-H157 originally obtained from ATTC (ATCC: #CRL-5802) was 
stably transfected with the pRSF91.dtTomato-Blasti plasmid[36]. Briefly, 1x106 NCI-
H157 cells were centrifuged at 90xg (1200 rpm, 7min.) at room temperature (RT), 
resuspended in 100 μl Amaxa nucleofector solution, 2 μg of vector DNA were added and 
carefully mixed. The cell suspension was transferred into an Amaxa cuvette and the cells 
transfected according to the manufacturer's program (Amaxa NucleofectorTM nuclear 
transfection apparatus - Lonza; Amaxa Kit Program: V X-0011). After the electroporation 
procedure, 500 μl of a pre-warmed culture medium containing serum and supplements 
were added. Culture medium composition was: RPMI media with 11 mM glucose and 2 
mM GlutaMAX™ (Cat. # 61870, Life Technologies) supplemented with 10% (v/ v) FBS 
(Life Technologies), 1% (v/ v) penicillin/ streptomycin (Life Technologies), 12 mM HEPES 
(Life technologies), 1 mM Sodium Pyruvate (Life Technologies) and 0.1 mM of non-
essential amino acids (Life Technologies). The cell suspension was then transferred into 
a 6-well cell culture plate and an additional 1 ml of the pre-warmed complete medium 
was added per well. Cells were incubated in a humidified incubator at 37°C and 5% CO2. 
Selection was at 30 μg/ml Blasticidin.  
Lung derived cancer-associated fibroblasts (CAF) were isolated as described 
previously[37]. The local ethics committee “Ethik-Kommission der Medizinischen 
Fakultät am Universitätsklinikum Tübingen” approved the study (project number 
396/2005V and 159/2011BO2) and a written informed consent was obtained from the 
patient. CAF were immortalized using a virus co-expressing hTERT and GFP (Lenti-
hTERT-eGFP; Cat No- LG508, BioGenova), as described[38–40]. CAF were cultivated in 
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RPMI media with 11 mM glucose and 2 mM GlutaMAX™ supplemented with 10% (v/ v) 
FBS and 1% (v/ v) penicillin/ streptomycin (all from Life Technologies).  
THP-1 cell line was purchased from ATCC (ATCC: TIB-202) cultured in RPMI media with 
11 mM glucose and 2 mM GlutaMAX™ supplemented with 10% (v/v) FBS and 1% (v/v) 
penicillin/streptomycin (all from Life Technologies). For monitoring during the co-
culture experiments, the THP-1 cell line was labelled with the fluorescent dye Cell 
tracker™ deep red (Invitrogen), according to manufacturer´s instructions.  
Tagged cell lines were used to monitor the different cell lines in co-culture. For 
fluorescent-based assays / analysis, cultures were performed with non-tagged cell lines. 
All the cultures were maintained at 37°C in a humidified atmosphere of 5% CO2 and 
were sub–cultured every 3-4 days.  
2.2 Peripheral blood-derived monocytes (PBM) 
Peripheral blood mononuclear cells (PBMC) were isolated from buffy coats obtained 
from Portuguese Blood Institute. The buffy coats were diluted in phosphate buffer 
saline (PBS) containing 2% (v/v) FBS and 2 mM EDTA, layered on top of Lymphoprep™ 
(Stemcell Technologies) and centrifuged at 950xg for 25 minutes. The PBMCs were 
recovered from the interface and were washed with PBS containing 2% (v/ v) FBS and 2 
mM EDTA. Monocytes were isolated from PBMCs by negative selection through 
magnetic separation using EasySep™ human monocyte isolation kit (Cat. #19359, 
Stemcell technologies) and cultured in RPMI media with 11 mM glucose and 2 mM 
GlutaMAX™ supplemented with 10% (v/ v) FBS and 1% (v/ v) penicillin/streptomycin 
(Basal Media). Primary monocytes monolayer cultures were maintained in basal media. 
2.3 Microencapsulated cultures 
NCI-H157 cell line was inoculated as a single cell suspension into 125 mL stirred-tank 
spinner vessels with flat centered cap and angled side arms (Corning) at a concentration 
of 3x105 cells/mL with an agitation range of 80-100 rpm to induce aggregation. After 3 
days, the spheroids were collected, centrifuged at low speed and combined with single-
cells of CAF and THP-1/PBM in a ratio of 1:1:1. The spheroid and single-cell mix was 
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encapsulated in 1.1 % (w/ v) of Ultra Pure Ca2+ MVG alginate (UP MVG NovaMatrix, 
Pronova Biomedical), prepared in NaCl 0.9 % (w/ v) solution. The control groups were 
the combination of the cellular components (double co-cultures) at a ratio of 1:1 or 
alone (mono-culture). The microencapsulation was performed in an electrostatically 
driven unit, VarV1 (Nisco, Zurich, Switzerland) to generate beads with a diameter 
ranging from 600-700 μm. Alginate polymerization was attained with a solution of 20 
mM BaCl2 in 115 mM NaCl/ 5mM L-Histidine pH 7.4. The microcapsules were collected, 
washed in NaCl 0.9 % (w/ v) and cultured in RPMI media with 11 mM glucose and 2 mM 
GlutaMAX™ supplemented with 10% (v/ v) FBS and 1% (v/ v) penicillin/ streptomycin at 
a concentration of 1-3 × 105 cell/mL. Cultures were maintained until day 21 when using 
the THP-1 cell line and until day 10 when using the PBM in stirred conditions and 50% 
media exchange was performed at each 3-4 days. Samples were collected periodically 
for determination of culture viability, cell concentration and culture 
characterization[26,29]. 
2.4 Spheroid and capsule size 
Capsule size was determined by measuring Ferret’s diameter and the average tumor 
spheroid diameter was determined by the average of three diameters per spheroid, 
using the open source ImageJ software version 1.47 m 
(http://rsbweb.nih.gov/ij/)[26,29]. 
2.5 Drug studies 
For the 3D-3-culture set up with the THP-1 cell line, the cultures were incubated with 
drugs 8 days after microencapsulation (day 11 of culture) at a concentration of 25 
capsule/mL. Dose-response curves were performed, and cultures were incubated with 
established concentrations of Paclitaxel (1x10-8 M), Cisplatin (1x10-6 M) and Blz945 
(1x10-7 and 1x10-6 M). Drug incubation lasted 6 days, with media replenishment. For the 
3D-3-culture set up with PBM, the cultures were incubated with BLZ945 4 days after 
microencapsulation (day 7 of culture) and the drug treatment lasted 3 days. After the 
drug treatment, metabolic activity, cell proliferation and apoptosis were assessed as 
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described below. For BLZ945 treatment, the macrophage phenotype was characterized 
by analysis of gene expression and immunodetection of cell surface markers. 
2.6 Cell viability  
Cell viability was assessed through a fluorescent membrane integrity assay to 
discriminate live from dead cells. Microcapsules were incubated with 10 µg/mL of 
fluorescein diacetate (FDA; Sigma-Aldrich) and 1 µM of TO-PRO® 3 (Invitrogen) and were 
observed under a fluorescence microscope (DMRB6000, Leica). Cells that accumulated 
the metabolized product of FDA were considered live and cells stained with TO-PRO® 3 
were considered dead. 
2.7 Apoptosis levels 
Apoptosis levels in cultures after exposure to a drug were measured by NucView 
Apoptosis Assay (Cat. #30062, Biotium). Treated and non-treated cultures were 
incubated with the caspase 3 substrate Nucview for 90 minutes at 37oC and fixed with 
4% (w/ v) formaldehyde with 4% (w/ v) sucrose in PBS for 20 minutes. The samples were 
mounted in Prolong® Gold antifade reagent containing DAPI (Cat. #P36935, Life 
Technologies). 
2.8 Cell proliferation 
Alginate microcapsules were dissolved in chelating solution (10 mM HEPES pH 7.4 with 
100 mM EDTA) and centrifuged either at 50xg for 1 minute to recover the tumor 
spheroids or at 400xg for 5 minutes to recover all the cell components. Pellets were 
solubilized in water subjected to ultra-sounds to lyse cells. Cell proliferation was 
measured by the amount of DNA present in the samples using Quant-iT™ PicoGreen® 
dsDNA Assay Kit (Invitrogen). DNA quantification was used to quantify the number of 
cells throughout the culture and in drug studies. Cell proliferation was also assessed by 
the incorporation of Click-iT® EdU (Life Technologies) during DNA replication, according 
to manufacturer’s instructions. Alginate microcapsules were incubated overnight with 
10 µM of EdU and fixed with 4% (w/ v) formaldehyde with 4% (w/ v) sucrose in PBS for 
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20 minutes. The samples were mounted in Prolong® Gold antifade reagent containing 
DAPI (Life Technologies) and the fluorescence was measured in an Andor spinning disk 
microscope (Revolution XD, Andor). 
2.9 Metabolic Activity 
The reduction capacity of the cultures was measured by Presto-Blue™ Viability Reagent 
reduction assay (Cat. #A13262, Life Technologies), according to the manufacturer´s 
instructions. The samples were incubated with 1x Presto blue for 30 minutes at 37oC 
and the fluorescence was read at 560 nm excitation and 590 nm emission in the micro 
plate reader Infinite®200 PRO (NanoQuant, Tecan Trading AG). ATP levels were 
measured by CellTiter–Glo® 3D Cell Viability Assay (Promega) according to the 
manufacturer’s instructions. Cell media was removed from each well and capsules were 
dissolved and centrifuged for 3 minutes at 500xg. Subsequently, equal volumes of 
CellTiter-Glo® reagent and the correspondent media were added to the wells. Plates 
were incubated at room temperature for 120 minutes on a shaker and luminescence 
was measured in the micro plate reader Infinite®200 PRO (NanoQuant, Tecan Trading 
AG).  
2.10 Immunofluorescence microscopy 
Samples were collected and fixed in 4% (w/v) formaldehyde with 4% (w/v) sucrose in 
PBS for 20 minutes. Then, they were dehydrated in 30% (w/ v) sucrose for approximately 
5 hours and embedded in Tissue-Tek® O.C.T. (Sakura) and frozen at -80C for 
cryosectioning. The frozen samples were sliced with a thickness of 10µm in a cryostat 
(Cryostat CM 3050S, Leica). The cryosections were permeabilized for 10 minutes with 
0.1% (v/v) Triton X- 100 (Sigma-Aldrich), blocked with 0.2% (w/ v) fish-skin gelatin (FSG; 
Sigma-Aldrich) in PBS for 30 minutes. Primary and secondary antibodies were prepared 
in 0.125% (w/v) of FSG in PBS and incubated for 2 or 1.5 hours. The samples were 
mounted in Prolong® Gold antifade reagent containing DAPI (Life Technologies). The 
primary antibodies used were anti-collagen type I, IV, fibronectin, vimentin (all from 
Abcam), N-cadherin (R&D systems), E-cadherin (Santa Cruz Biotechnology) and 
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phalloidin for detection of F-actin (Invitrogen). Samples were visualized using a 
fluorescence microscope (DMRB6000, Leica). 
2.11 Light-sheet fluorescence microscopy 
The custom-made light-sheet microscope used for these experiments is an evolution of 
the SPIM-Fluid system [41]. CW lasers with excitation wavelengths of 488 nm (Cobolt, 
MLD 50 mW), 515 nm (TOPTICA, iBeam Smart 515-S 100 mW) and 637 nm (Cobolt, MLD 
150 mW) are used for excitation. The light sheet is created by a pair of galvanometric 
mirrors (Thorlabs, GVSM002), conjugated with the illumination objectives (Nikon, 
PlanFluor 4x, NA 0.13). We use a 50/ 50 beamsplitter cube (Thorlabs, CCM1-BS013) to 
create double side illumination, increasing the quality of the images. On each arm, laser 
beams are expanded using a telescope system, composed of two achromatic doublets 
(Thorlabs, AC254-050-A-ML (f= 50 mm) and AC254-200-A-ML (f= 200 mm)), creating a 
flat top Gaussian beam profile. A relay lens set, with two achromatic lenses (Thorlabs, 
AC254-075-A-ML (f=75 mm)) is used in the right arm, so the planes are properly 
conjugated. Detection is performed in an up-right configuration, using water dipping 
objectives (Nikon, PlanFluor 10x, NA 0.3). An achromatic doublet (AC254-200-A-ML) 
forms an image onto a Hamamatsu Orca Flash4.0 cMOS camera chip. Different 
emissions filters (Chroma and Semrock: 520/ 15 (GFP), 590/ 50 (tdTomato), 638LP (Cell 
tracker deep red)) are selected using a motorized filter wheel (Thorlabs, FW102C). 
Samples were fixed as described above, and directly imaged without any further 
manipulation. In order to increase the throughput of the system, samples are loaded 
into FEP tubes (which refractive index is matched to water, 1.33) and transported 
towards the detection objective field of view using a syringe pump (Tecan, Cavro 
Centris). Scanning of the encapsulated aggregates is performed by vertical translation 
of the tubes, using a motorized stage (PI M-501.1DG), through a fixed horizontal light 
sheet plane. This allowed a straightforward the evaluation of hundreds of 3D-3-cultures 
with different co-culture combination and at different time points. All the components 
of the microscope are controlled using the custom-made software (LabView) and the 




Samples were fixed as described above and embedded in 1% (w/ v) high melting 
temperature agarose (Lonza), dehydrated in graded alcohols and then embedded in 
paraffin wax. Paraffin blocks were sectioned (3 mm) for Hematoxylin & Eosin and 
immunohistochemical staining. Immunohistochemistry was carried out in a BenchMark 
ULTRA Automated IHC/ISH slide staining system from Ventana Medical Systems, Inc. 
according to instrument specifications. Briefly, antigen retrieval was performed in the 
instruments using the standard antigen retrieval solutions. Staining was performed 
using as primary antibodies the following clones:  Anti-CD45 (clone 2B11 + PD7/26 from 
Agilent/DAKO), CD68 PG-M1 clone PGM1 from Agilent/DAKO and CD163 (clone 10D6 
from Leica Biosystems). OptiView DAB IHC Detection Kit from Ventana Medical Systems, 
Inc. was used as the visualization system for all. Sections of human tonsil were included 
in all slides as positive and negative controls. The resulting staining was evaluated by 
bright field microscopy. Quantification was performed using the image analysis 
software Image J, by applying the colour deconvolution plug in and determining the 
DAB-positive and negative areas. The results are expressed as the percentage of positive 
staining within the alginate capsule. 
2.13 Flow Cytometry 
Alginate microcapsules were dissolved with a chelating solution as indicated above and 
centrifuged at 600xg for 5 minutes. To analyze the surface expression of immune cells, 
CD45 (Cat. #555483, BD Pharmingen™, San Diego, USA), CD163 (Cat. #FAB1607A, R&D 
Systems) and CD206 (Cat. #321114, Biolegend) were used. The cell suspensions were 
incubated with the primary antibodies conjugated with a fluorophore for 45 minutes in 
PBS. The samples were centrifuged, washed and analyzed in a CyFlow space (Partec). 
2.14 Cytokine analysis 
Supernatant media were collected at day 4 and day 17 and centrifuged at 1000g for 5 
minutes. Samples were snap- frozen and stored at -80oC until use. The Bio-Plex Pro™ 
Human Chemokine Panel, 40-Plex #171AK99MR2 was applied and samples were 
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analyzed in a Bio-Plex® 200 System according to the manufacturer´s protocol 
(http://www.bio-rad.com/webroot/web/pdf/lsr/literature/10031990.pdf).  
2.15 Gene expression analysis  
Alginate microcapsules were dissolved with a chelating solution as indicated above, 
centrifuged at 400xg for 5 minutes. Pellets were snap- frozen and kept at -80oC until 
RNA isolation. Total RNA was extracted from samples with the High Pure Isolation kit 
(Roche) and then converted to cDNA with Transcriptor High Fidelity cDNA synthesis kit 
(Roche), both according to the manufacturer’s instructions. Real Time-PCR was 
performed using SYBR-Green (SYBR Green I Master Kit, Roche) in LightCycler 480 
(Roche). Gene expression calculations were based in relative quantification using the 
comparative CT method (2-ΔΔCT) and RPL22 and HPRT1 endogenous expression were 
used as controls.  
3. RESULTS 
3.1 Advanced stage NSCLC spheroids maintain mesenchymal phenotype 
in 3D-3-culture 
With the goal of establishing in vitro tumor models of NSCLC that incorporate the 
myeloid compartment found at the tumor site, 3D-3-cultures were established. Our 
strategy employed alginate microencapsulation and stirred culture described previously 
by our group [26,29], and summarized in Fig. 4.1 – A. The 3D-3-cultures were set up 
within alginate microcapsules of an average diameter of 652 ± 26 µm, with three cellular 
compartments – NSCLC (NCI-H157) tumor spheroids, cancer associated fibroblasts (CAF) 
and a monocytic cell line (THP-1) (Fig. 4.1 – B). Microencapsulated cells were maintained 
in stirred suspension culture for up to three weeks and presented high viability 
throughout culture time (Fig. 4.1 – C). Cell proliferation was homogeneous within the 
tumor spheroids and also in the remaining cellular compartments, as evidenced by Edu 
staining (Fig. 4.2 – A). Cell proliferation resulted in a 10-fold increase in tumor cell 
concentration by week 3 (Fig. 4.2 – B), which was comparable to tumor cell growth in 
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monocultures and in double co-culture controls. Even though no statistical differences 
in the average spheroid diameter were observed between the 1st and 3rd week of 
 
Figure 4.1 - Experimental approach and culture monitoring over time. A) Schematic 
representation of the experimental approach: 1 - Tumor cells were inoculated as single cells in 
stirred-tank vessels to promote cell aggregation. 2 - After 3 days, tumor spheroids and single-
cells of CAF and THP-1 or PBM were mixed and encapsulated in alginate, resulting in 
microcapsules enclosing the three cellular components. 3 - The alginate microcapsules were 
maintained in long-term culture while culture characterization and drug treatments were 
performed. The representation is not to scale. B) Alginate microcapsules of the 3D-3-cultures in 
the 1st and 3rd week of culture visualized by light-sheet fluorescence microscopy. The cellular 
types are labelled by tdTomato (red) – NSCLC spheroids; GFP (green) – CAF; Cell tracker™ (blue) 
– THP-1. C) Live/dead assay of 3D-3-cultures in the 1st and 3rd week of culture: FDA (green) – live 
cells; TO-PRO-3 (red) – dead cells. Scale bars represent 100 µm. 
culture, the number of spheroids per capsule increased over time and a high dispersion 
in the diameter of spheroids was observed in the 3rd week of culture (supplementary 
Fig. S4.1), which is in line with the increase in cell concentration. These results suggest 
that the presence of stromal and monocytic cell types had no major effect on tumor 
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proliferation and that there were no nutrient or spatial restrictions within the 
microcapsules. 
Along the culture period, multiple spheroids and clusters of cells were found spread 
within the microcapsules in 3D-3-cultures, constituted by tumor, CAF and THP-1 cells 
(Fig. 4.1 – B). In contrast, 1-3 large spheroids were found in the microcapsules of tumor 
monocultures (Fig. 4.2 – A). Tumor spheroids within 3D-3-cultures were composed of 
cells positive for N-cadherin and vimentin, with low E-cadherin expression (data not 
shown) and presented loose cell architecture, as evidenced by F-actin staining (Fig. 4.2 
– C), showing that NCI-H157 cells maintain their typical mesenchymal phenotype upon 
microencapsulated spheroid culture. 
Moreover, collagen type I (Col I), collagen type IV (Col IV) and Fibronectin (FN) 
accumulated in the alginate microcapsules intercalated with cell spheroids, clusters and 
single cells, in a tissue-like phenotype (Fig 4.2 – D). The accumulation of ECM (e.g. Col I) 
was marked in the edges of the alginate microcapsules, in which the cells aligned in 
between the collagen fibers, displaying a migratory phenotype. These results suggest 
that the model set up was permissive to cell movement within the microcapsules, 
accommodating cell-cell interactions occurring between the different cell 
compartments, which may be promoted by the ECM accumulation[42,43]. 
3.2 Myeloid cells infiltrate into the tumor spheroids and display a TAM-
like phenotype 
To fully assess the model’s capability of recapitulating the immune contexture, namely 
the trans-polarization of monocytic THP-1 cells into myeloid M2-like macrophages and 
their infiltration into human NSCLC tumors, the M2-like macrophage population was 
characterized in detail. 
CD45+ (protein tyrosine phosphatase, receptor type, C/PTPRC; pan leukocyte marker) 
cells were detected in small clusters around larger tumor spheroids and as single-cells 




Figure 4.2 - Phenotypic characterization of tumor spheroids and ECM accumulation in alginate 
microcapsules. A) Cell proliferation and morphology of tumor spheroids in mono- (upper panel) 
and 3D-3-cultures (lower panel) at day 14 of culture. From the left: Edu (green) – proliferative 
cells; tdTomato (red) - NCI-H157; DAPI (blue) – Nuclei and merge of all channels. B) Tumor cell 
concentration profile of mono-, double co-cultures and 3D-3-culture along 3 weeks of culture; 
data are mean ± SEM from three independent experiments. C-D) Immunofluorescence 
microscopy of 3D-3-culture alginate microcapsules in 10 µm thick cryosections, at day 21, of C) 
Tumor cells: Vimentin (red), F-actin (Phalloidin; green); N-cadherin (red) and Nuclei (DAPI; blue). 
Scale bars represent 50 µm and D) ECM: Collagen type I (green), Collagen type IV (red), 
Fibronectin (green) and Nuclei (DAPI; blue). Scale bars represent 100 µm. 
controls (Fig.4.3 – A). Furthermore, the presence of CD45+ cells distributed within tumor 
3D-3-CULTURE: a tool to unveil macrophage plasticity within the tumor microenvironment 
103 
spheroids suggests that alginate microcapsules allow cell migration and that the 
generated TME within the microcapsules drives the infiltration of myeloid cells into the 
tumor spheroids. The immunohistological staining of CD68 (Cluster of Differentiation 
68) (Fig. 4.3 – A), which is highly expressed in tissue macrophages, was similar to CD45. 
CD68 expression together with cell morphology supports differentiation of most 
monocytes into macrophages.  
Cells positive for CD163 (scavenger receptor for the hemoglobin-haptoglobin complex), 
an M2-like macrophage marker, were detected in 3D-3-cultures (Fig. 4.3 – A). CD163+ 
cells could also be detected in tumor-immune, but in CAF-immune co-cultures and THP-
1 monocultures only residual levels were detected (Fig. 4.3 –  A and supplementary 
Table S4.1). This data strongly suggests that the presence of both NCI-H157 spheroids 
and CAF are required to promote the differentiation of monocytic cells towards M2-like 
macrophages and that polarization of THP-1 cells depends on the interaction with other 
cell types. While most of the CD45+ cells were detected in clusters, on the edges and 
inside the spheroids, CD163+ cells were mostly infiltrated in tumor spheroids (Fig. 4.3 – 
A). 
We also analyzed the secretory profile of the cultures, screening for the presence of 
cytokines and chemokines associated with immunosuppressive environment and 
invasive phenotype (Fig. 4.3 – B). Tumor cells in monoculture secreted IL4, IL13, IL10 
and CXCL1 cytokines previously described as associated with macrophage recruitment 
and induction of an M2-like activation state[44–48]. Moreover, in 3D-3-cultures, there 
was an increased secretion of metalloproteinase-9 (MMP9) and of cytokines typically 
expressed by M2-like macrophages, namely CCL22 and CCL24[49–51]. The secretion 
profile and immunodetection show that M2-like macrophages are present in 3D-3-
cultures. 
We also established 3D-3-culture models with donor-derived peripheral blood 
monocytes (PBM), isolated from peripheral blood mononuclear cells (PBMC). PBM 
maintained high cell viability over 7 days when cultured as 3D-3-cultures. After 4 days, 
approximately 70 to 80% of CD45+ cells expressed the M2-like markers CD206 and 
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CD163 while in microencapsulated mono-cultures (Microencapsulated PBM) this 
percentage was significantly lower, around 2 to 6% (Fig. 4.3 – C). In comparison with the 
2D cultures (2D PBM), the differences in percentage of differentiated cells were less 
evident, although median fluorescence intensity of each marker was higher in 3D-3-
culture (Sup. Fig. S4.2). This suggests that the phenotype of the macrophages expressing 
 
Legend on the next page 
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Figure 4.3 - Characterization of the immunosuppressive TME in 3D-3-cultures. A) 
Immunohistochemistry staining of alginate microcapsules in 3 µm thick paraffin sections after 3 
weeks of culture with the immune markers CD45, CD68 PG-M1 and CD163. From the left: Tumor 
and monocyte mono-cultures, CAF-monocyte and tumor-monocyte double co-cultures and 3D-
3-culture. Scale bars represent 100 µm. B) Heat map of the cytokine profile of IL4, IL13, IL10, 
CCL22, CCL24, CXCL1, MMP1 and MMP9, represented in z-score. From left: Mono-cultures of 
tumor, CAF and monocytes, double co-cultures of tumor-CAF, tumor-monocyte, CAF-monocyte 
and 3D-3-culture. All the proteins presented had a significant differential expression (p≤0.05) by 
ANOVA analysis. C) Immunodetection of cells double positive for the leucocyte marker CD45 and 
M2-associated markers CD163 and CD206 of peripheral blood derived macrophages 4 days after 
isolation in monolayer mono-culture (2D PBM) and microencapsulated mono-culture 
(Microencapsulated PBM) and in 3D-3-cultures (with tumor cells and CAF). Data are mean ± SEM 
from up to six independent experiments. * indicate significant differences between different 
cultures; (***p < 0.001; **p < 0.01) by an unpaired t-student test. 
M2-like markers was different, pointing to a higher maturation in the 3D-3-culture. 
Altogether, these observations indicate that not only an immortalized monocytic cell 
line, but also primary monocytes polarize into M2-like macrophages in the 3D-3-culture 
setup. 
3.3 Effects of chemo- and immunotherapies can be assessed in 3D-3-
culture 
As proof-of-concept that the 3D-3-culture setup allows the study of the effect of drugs 
in an immunity relevant context, we challenged it with Cisplatin and Paclitaxel, two 
chemotherapeutic drugs routinely used in the treatment of NSCLC [52,53], as well as 
BLZ945, an immunomodulatory drug targeting CSF1R (Colony Stimulating Factor 1 
Receptor) [16,17,54,55]. This receptor was upregulated over time in 3D-3-culture (data 
not shown) and previous reports showed that its inhibition leads to decreased 
proliferation of BM-derived monocytes and promotes repolarization of M2-like 
macrophages into an M1-like phenotype[16,18]. 
Chapter IV 
106 
Dose-response curves for Cisplatin and Paclitaxel were established for tumor 
monocultures and the IC50 value was determined by measuring ATP levels and 
confirmed through additional readouts (resazurin reduction and DNA quantification) 
(Sup. Fig. S4.3).  
Treatment with Paclitaxel led to a reduction of the ATP levels of tumor, CAF and 
monocyte monocultures, which ranged from 58 to 37% of the control (Fig. 4.4 – A). The 
3D-3-culture and CAF-monocyte co-culture presented a metabolic activity of 
approximately 80% upon treatment, showing less sensitivity to the drug comparing with 
the mono-culture (Fig. 4.4 – A and sup. Fig. S4.4 – A). The lower drug response in 3D-3-
cultures reflects the lower induction of apoptosis throughout the cultures, as observed 
by NucView™ fluorescence staining (Fig. 4.4 – C and sup. Fig. S4.4). Nevertheless, 
proliferating cells could still be detected in 3D-3-cultures, as well as in co-culture 
controls, in tumor spheroids and in the stromal and immune compartments. These data 
suggest that there is a subset of tumor and immune cells not affected by the drug (Fig. 
4.4 – D). 
In contrast to what was observed for Paclitaxel, no significant differences were observed 
between the metabolic activity of tumor monoculture and the 3D-3-culture upon 
treatment with Cisplatin (Fig. 4.4 – B). The ATP levels of monocyte and CAF 
monocultures, as well as monocyte-CAF co-cultures ranged from 7 to 23% of the control, 
showing that all cell compartments were affected by the treatment (Fig. 4.4 – B). The 
generalized effect of cisplatin was also evident in the apoptosis fluorescence staining, 
in which apoptotic cells can be observed throughout the tumor, stromal and immune 
compartments (Fig. 4.4 – C and sup. Fig. S4.4). Concomitantly, hardly any proliferative 
cells were detected after treatment in the 3D-3-culture (Fig. 4.4 – D). 
Concerning BLZ945 treatment, there were no significant alterations in ATP levels in THP-
1 and tumor monocultures relative to the non-treated controls (Fig. 4.5 – A), suggesting 
that the concentrations employed were not acting through generalized toxicity 
mechanisms. BLZ945 induced a decrease in CD163 gene expression in 3D-3-cultures 
after drug treatment and an increase in the expression of the M1-associated gene CCR7 
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Figure 4.4 - Chemotherapeutic treatment in 3D-3-culture. Metabolic activity (ATP levels) of A) 
Paclitaxel (10-8 M) and B) Cisplatin (10-5 M) treated mono-cultures of tumor, monocyte and CAF, 
double co-culture of CAF-monocyte and 3D-3-culture. Data are mean ± SEM from three 
independent experiments. * indicate significant differences between tumor and other cultures 
by an unpaired t-student test (**p<0.01, *p<0.05). Immunofluorescence images of 3D-3-culture 
after treatment and respective controls for analysis of C) apoptosis: NucView™ (green) - 
apoptotic cells; tdTomato (red) – NCI-H157; DAPI (blue) - nuclei; and D) proliferation: Edu (green) 
- proliferative cells; tdTomato (red) - NCI-H157; DAPI (blue) - nuclei. Scale bars represent 100 µm. 
(C-C chemokine receptor type 7; Fig. 4.5 – B). The expression of PTPRC (CD45) also 
increased up to 2-fold, although there was no evidence of alteration of the numbers of 
immune cells either due to apoptosis or proliferation (Fig. 4.5 – B). Gene expression of 
CSF1R increased up to 1.8-fold (Fig. 4.5 – B), in accordance to what has been previously 




Figure 4.5 - Immunotherapeutic treatment in 3D-3-culture. A) Metabolic activity (ATP levels) of 
cultures after treatment with 10-7 and 10-6 M of BLZ945 in tumor and monocyte mono-cultures 
and 3D-3-culture. Data are mean ± SEM for three independent experiments. B) Heat map with 
fold increase in gene expression of macrophage markers after treatment with chemotherapeutic 
and immunotherapeutic drugs in 3D-3-culture, relatively to the non-treated controls. Data are 
mean from three independent experiments. * indicate significant differences of treated 
conditions to control by a two-way ANOVA and a Sidak’s multiple comparison test (***p < 0.001, 
*p < 0.05).  C) Immunodetection of cells double positive for the leucocyte marker CD45 and M2-
associated markers CD163 and CD206 of 3D-3-cultures with donor-derived monocytes with and 
without treatment with BLZ945 (10-7 and 10-6 M). Data are mean ± SEM from three independent 
experiments. * indicate significant differences between treated conditions and control by a 
paired t-student test (*p < 0.05). D) Immunofluorescence images of (10-6 M) BLZ945 treated 
cultures, showing apoptosis in the upper panel: NucView™ (green) - apoptotic cells; tdTomato 
(red) – NCI-H157; DAPI (blue) - nuclei; and proliferation in the lower panel: Edu (green) - 
proliferative cells; tdTomato (red) – NCI-H157; DAPI (blue) – nuclei. Scale bars represent 100 µm. 
cisplatin treatment, while expression of CD68 and CD163 remains unchanged (Fig. 4.5 – 
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B). This may suggest that, in addition to the depletion of immune cells, the phenotype 
of the surviving macrophage population is also modulated in cisplatin-treated cultures. 
In fact, several reports have indicated that cisplatin plays a role in immunomodulation, 
specifically by altering the ratio of M2/M1-like macrophages[56,57]. 
In PBM-3D-3-cultures treated with 1x10-6 M of BLZ945, there was a reduction of up to 
39% of CD206+ cells and up to 45% reduction in CD163+ cells (Fig. 4.5 – C). These results 
suggest that the treatment with BLZ945 leads to a decrease in the M2-like macrophage 
population in 3D-3-cultures both with the THP-1 cell line and with PBM, which may be 
attributed to a repolarization from M2- to the M1-like macrophage phenotype, as 
previously reported [16,18]. This repolarization of the macrophage compartment did 
not have a significant impact on the viability of tumor cells in 3D-3-culture (Fig. 4.5 – A, 
D). Nevertheless, the results demonstrate that our model is suitable to perform 
immunomodulation studies in vitro, allowing the depiction of specific effects on each 
cellular component. 
4. DISCUSSION 
Extensive studies have shown that the tumor microenvironment (TME) is important for 
disease progression and drug response, however, its integration into drug screening 
platforms has been difficult due to the lack of cellular models amenable for throughput 
screening. In this work, we describe the development of a 3D-3-culture system, 
combining alginate microencapsulation and stirred culture, which incorporates tumor 
spheroids, cancer-associated fibroblasts and trans-polarized macrophages in an 
environment where the dynamic interaction between each compartment is 
recapitulated. Our results demonstrate that the 3D-3-culture allows polarization of a 
monocytic cell line (THP-1) and peripheral blood-derived monocytes (PBM) into tumor-
associated macrophages (TAM) and infiltration in the tumor tissue, which can be 
modulated upon exposure to chemotherapeutic and immunomodulatory drugs. This 
system allows the study of monocyte recruitment, as well as, phenotype induction in a 




In the 3D-3-culture, NCI-H157 tumor cells maintained their proliferative state and 
displayed phenotypic markers typical of aggressive stages of NSCLC, such as expression 
of N-cadherin and vimentin, coupled with low expression of E-cadherin. This pattern, 
typical of late-stage epithelial-to-mesenchymal transition, was also described for 
immunohistochemical analysis of human tissue samples from primary tumors of lung 
squamous cell carcinoma and correlates with advanced stage tumors[58]. Although no 
major differences in the proliferation and histological markers of tumor cells were 
observed upon co-cultivation with CAF and myeloid cells, there was an evident spatial 
remodeling of the different cell compartments within the alginate microcapsules over 
the course of the culture. This can be attributed to the ECM accumulation observed 
within the microcapsules (Col I, IV and FN) and the secretion of metalloproteinases 
(MMP1 and MMP9) and suggests an increased invasive phenotype in the 3D-3-culture. 
This secretory profile was previously described for co-cultures of tumor cells, fibroblasts 
and macrophages, and is associated with the acquisition of higher metastatic 
potential[34,59].  
The 3D-3-culture model allowed for the recapitulation of key hallmarks of lung cancer 
immune microenvironment. Early reports indicate that spheroids are suitable for 
tumor-immune interaction studies[60,61], as tumor architecture is important in 
establishing the immunosuppressive TME found in human tumors[62–65]. In the 3D-3-
culture, CD68 and CD163+ cells were detected, pointing to macrophage polarization into 
an M2-like phenotype, as described for primary tumors of NSCLC[66,67]. Moreover, a 
high proportion of CD163+ cells was detected within tumor spheroids, demonstrating 
that the developed model was conducive to cell migration, as occurs with the myeloid 
infiltrate in human lung cancers. Although the detection of CD163+ cells was also 
observed in tumor-immune and CAF-immune co-culture controls, however, at a much 
lower level. This is in line with previous reports suggesting that the stromal 
compartment is also primarily involved in the recruitment and activation of monocytes 
in the TME[68], as CAF exhibit an activated fibroblast phenotype, with altered secretory 
profile and ECM production[23,69]. In fact, in co-culture models of blood monocytes 
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with breast cancer or CAF spheroids, monocyte migration was higher towards CAF 
spheroids, a phenotype linked to overexpression of CCL2[70]. 
A significant feature of the developed 3D-3-culture model for tumor modelling is the 
use of an inert scaffold, as the introduction of physiologically relevant ECM remains a 
fundamental challenge for tumor modelling in current in vitro settings[22]. Routinely 
used Matrigel or collagen-based artificial ECM substrates do not represent the 
predominant ECM proteins found in the target tissue[22]. We demonstrate that the 
alginate microcapsules allow the accumulation of collagen type I and IV, forming 
collagen fibers that intercalate cells, and fibronectin, resembling the tissue architecture 
and contributing to the migration and tissue remodeling within the microcapsules. This 
cell remodeling allows cell interactions to occur naturally, resulting in a cell distribution 
within the alginate microcapsules that presents features existent in the human tissue of 
NSCLC patients, such as macrophage infiltration and extravasation of tumor cells to the 
surrounding stroma[71]. 
The accumulation of a cocktail of soluble factors plus the cell-cell interactions observed 
have a key role in modulating the phenotype of macrophages in the 3D-3-culture model, 
since the polarization of macrophages was not promoted by the supplementation with 
cytokines. Analysis of the secretory profile in the 3D-3-culture model evidenced the 
formation of an immunosuppressive environment. Therefore, the induction of an M2-
like phenotype observed may be explained by the accumulation of IL4, IL13, IL10 and 
CXCL1, cytokines previously described to contribute to the referred phenotype[44–46]. 
Furthermore, a specific accumulation of CCL22 and CCL24 in week three of the 3D-3-
cultures was observed. Both cytokines were previously reported to be produced by 
TAMs and are involved in the recruitment and differentiation of regulatory T cells to the 
TME, which correlate with poor prognosis and suppress antitumor-specific immune 
responses[15,51,72]. MMP9 was also upregulated primarily in 3D-3-cultures. This 
metalloprotease was reported to be expressed by TAMs from primary lung cancer tissue 
and its expression is correlated with disease progression in NSCLC patients[73]. Recent 
reports also highlight the important role of cell-cell interactions. Specifically, binding of 
tumor-associated mucin O-glycans to lectin receptors on immune cells may promote 
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immune-tolerance and emergence of immune-resistant cancer cell variants[74–77] 
These studies were important to help dissect the TAM inducing stimuli, however, these 
were mainly conducted in models where the TME complexity is not represented (tumor 
cell monocultures), in a non-human setting (GEMM models) or using targeted 
approaches towards identifying the partners of previously described tumoral 
glycoconjugates or lectins. The developed 3D-3 model allows for cell-cell interaction 
between the different cell compartments. Therefore, it could be used to surpass some 
of the drawbacks of the above described models, and to allow the dissection of the 
concerted action of both soluble factors and cell-cell interactions in response to a given 
stimuli, namely anticancer therapy. 
The development of novel and improved therapeutics is an area of intense study in 
cancer research but still presents huge attrition rates. One of the limitations of current 
pre-clinical platforms is the lack of integration of multiple TME compartments. The use 
of platinum-based compounds, such as cisplatin, for chemotherapy has shown clinical 
efficacy against several solid tumors, including NSCLC[78]. Paclitaxel, a microtubule-
stabilizing agent, is another standard-of-care drug that induces cell death through 
interruption of mitosis[79]. Here we show that challenging our model with each 
compound led to different results. Although both drugs ultimately lead to cancer cell 
apoptosis, they present different mechanisms of action that might explain the different 
results obtained: paclitaxel is a microtubule stabilizer, whereas cisplatin crosslinks DNA. 
Treatment with cisplatin led to a generalized tumor cell apoptosis, which was not 
affected by the presence of other cells in the TME. Paclitaxel, on the other hand, leads 
to a less extensive apoptosis induction in the 3D-3-culture than in mono-cultures, 
suggesting that the reciprocal interactions occurring between the stromal and immune 
compartment may alter cell´s sensitivity to the drug. Such discrepancies are often 
observed when comparing response of in vitro drug screening platforms, devoid of TME, 
and in vivo drug sensitivity, highlighting the importance of incorporating the TME 
components when addressing drug response[80]. This shows that the developed model 
can aid in deciphering the microenvironmental regulation of therapeutic response. 
Moreover, the immunomodulatory effects of each chemotherapeutic agent could also 
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be depicted. Cisplatin treatment led to a significant increase in CCR7 expression in the 
surviving macrophage population, which was not evident for paclitaxel treatment. In 
fact, increasing preclinical and clinical evidence has shown that cisplatin can modulate 
the immune system alone or in combination with immunotherapies[56]. Early studies 
had already linked cisplatin action to the activation of macrophages into an antitumoral 
state[81,82]. These findings demonstrated that cisplatin significantly increases antigen-
presenting ability of murine macrophages. It also alters the macrophages´ secretory 
profile. Costimulatory factors such as  IL1, IL6, TNFα and NO, enhance autocrinally the 
antigen presenting and antitumor ability of other immune cells present in the 
TME[81,82]. More recently, adjuvant cisplatin chemotherapy increased antitumor 
efficacy through an increase of antigen specific CD8+ cells systemically and 
intratumorally and by shifting the M1-/M2-like phenotype ratio in mice[83]. On the 
other hand, paclitaxel tumor reducing effects seem to also involve a direct stimulation 
of TAM’s cytotoxicity[84,85] and cytokine release, namely IL-12, TNFα and iNOS by 
TAM[84,86]. However, its potential for inducing immunogenic cell death (ICD) by mitosis 
catastrophe-mediated tumor cell death is not fully understood[84].  
Upon challenging the 3D-3-culture with the CSF1R inhibitor BLZ954, a significant 
decrease in the expression of CD206 and CD163 in the macrophage population was 
observed. CSF1R activation has been linked with proliferation and survival of 
macrophages, but also with the expression of M2-like genes[87]. Its inhibition is a 
promising anticancer strategy showing reduced tumor size and improved survival in a 
mouse breast tumor model[88] and leading to a significant clinical activity in 
patients[17]. Several reports have also shown that the effect of CSF1R inhibition in TAM 
could not only be dependent on macrophage depletion, but rather a repolarization into 
a more M1-like anti-tumor macrophage phenotype[16,55]. These effects could be 
recapitulated  in our model which indicates that it is able to depict the 
immunomodulatory effects previously observed for mouse models in a human relevant 
TME context[16,55]. 
In conclusion, we have developed a 3D-3-culture model that mimics the dynamic 
interaction between tumor, stromal and immune compartments, alongside 
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accumulation of ECM and secreted factors. This contributed to the maintenance of key 
features of advanced stage lung carcinoma, including the immunosuppressive 
environment. This model allowed the activation of monocytes into a TAM-associated 
phenotype without addition of external factors and the macrophage phenotype could 
be modulated upon treatment with immune-targeting and chemotherapeutic drugs. 
One of the main features of the 3D-3-culture system is that it is scalable, compatible 
with drug screening platforms and flexible, combining the use of cell lines with primary 
immune cells (PBM). This system is also transferable to other pathologies, by using 
tumor cell lines of other cancer types, such as breast cancer. Establishing in vitro models 
using cell lines enables the labelling of individual cell types. These models can be 
complemented with single cell imaging for tracking the response of specific cell 
compartments to a given stimuli, or with gene editing tools, such as CRISPR–Cas9 
system, for the development of more translatable in vitro models of disease[22].  
Nevertheless, this culture system may also be adapted to incorporate patient-derived 
tumor samples for ex vivo assessment of therapeutic efficacy using precision medicine 
approaches for translational research. 
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5. SUPPLEMENTARY MATERIAL 
Supplementary Table S4.1 - Quantitative analysis of CD68 and CD163 
immunohistochemistry staining in the different culture groups. Data is expressed as 
the percentage of positive staining among the total cell area.  Data are mean + SD of a 
minimum of 7 capsules per condition. 






CD68 (%)  - ≥ 99 ≥ 95 21.8 ± 9.2 21.4 ± 8.6 








Supplementary Figure S4.1 - Analysis of tumour spheroid diameter over time (day 3 
and day 21) for the different culture groups: tumour monocultures, tumour-CAF and 
tumour-monocyte co-cultures and 3D-3-culture. Data are mean ± SD from 12 capsules 





Supplementary Figure S4.2 - Mean fluorescence intensity of cells double positive for 
the leucocyte marker CD45 and M2-associated markers CD163 and CD206 of 
peripheral blood derived macrophages 4 days after isolation in monolayer mono-culture 
(2D PBM) and microencapsulated mono-culture (Microencapsulated PBM) and in 3D-3-




Supplementary Figure S4.3 – Comparison between methods to determine cell viability 
in tumour monocultures, when exposed to the half maximal inhibitory concentrations 
(IC50) of Cisplatin and Paclitaxel. Cell titer Glo measures ATP levels, Presto blue 
measures resazurin reduction capacity and Picogreen measures dsDNA. Data are mean 
+ SEM of up to 3 independent experiments. 
3D-3-CULTURE: a tool to unveil macrophage plasticity within the tumor microenvironment 
117 
 
Supplementary Figure S4.4 - Analysis of apoptosis and proliferation of cultures upon 
drug treatment. Immunofluorescence images of monocultures after treatment and 
respective controls for analysis of (A) apoptosis: Nucview (green) - apoptotic cells; 
tdTomato (red) – NCI-H157; DAPI (blue) - nuclei; and (B) proliferation: Edu (green) - 
proliferative cells; tdTomato (red) – NCI-H157; DAPI (blue) – nuclei. Scale bars represent 
100 µm. C) Quantitative analysis of apoptotic cells in the tumour cell subset in mono- 
and 3D-3-cultures (green vs. red channel). Data are mean + SEM of a minimum of three 
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1. DISCUSSION AND PERSPECTIVES 
Cancer therapies have long evolved from indiscriminately affecting proliferative cells, 
using untargeted approaches, which invariably result in toxic side effects and often lack 
of efficacy. Currently, development of antitumor therapeutics can be divided into two 
main categories, according to the strategy pursued: i) identification of cell-intrinsic 
genetic drivers of tumorigenesis and cancer cell genetic dependencies that may 
constitute druggable molecular targets, and ii) identification of tumor 
microenvironment (TME) drivers of tumor progression, therapeutic resistance and 
suppression of antitumor immunity that may provide a rational for combination 
therapies. 
The work carried out in this thesis aimed at the development of approaches with 
potential for clinical translational in both categories: A) implementation of a therapeutic 
strategy to target Basal-Like Breast Cancer (BLBC) genetic dependencies and B) 
development of 3D cellular models for preclinical research, incorporating the crosstalk 
between tumor cells and cells from the TME.  
1.1 Strategies to target cancer-intrinsic vulnerabilities 
In Chapter II, we explored previously identified molecular targets for their potential for 
BLBC therapy and evaluated a therapeutic strategy based on rAAV-mediated shRNA 
delivery for their targeting and preclinical efficacy evaluation. Among the hits identified 
by Petrocca el at., proteasome machinery subunits PSMA2 and PSMB4 and 
antiapoptotic protein MCL1 were identified as the most promising since BLBC cells 
presented selective sensitivity to their downregulation[1]. 
Although these are genes expressed in normal cells and in multiple tissues, we reasoned 
that the specificity of neoplastic cells dependency on these mechanisms could be 
exploited therapeutically. The exploitation of molecular targets for cancer has had a 
profound impact in several malignancies and drastically increased the outcome of 
genetically defined patient subsets[2]. Examples include targeting BCR-ABL in chronic 
myeloid leukemia (CML), B-Raf proto-oncogene, serine/threonine kinase (BRAF) or MEK 
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kinase for melanoma and advanced NSCLC, EGFR and ALK for specific subsets of lung 
cancer and ERBB2 for HER2-overexpressing breast cancer[3]. However, molecular 
targets are not an option for every tumor type. Cytotoxic chemotherapy is still the 
primary treatment for patients with basal-like triple negative breast cancer (BL-TNBC). 
These tumors present a high response rate to taxane and anthracycline-based 
chemotherapy; however, overall prognosis for these patients is poor due to the high 
likelihood of recurrence and metastasis[4]. Potentially actionable molecular alterations 
in this subtype have been uncovered by the widespread application of different omics 
technologies, such as  protein from the PI3K/MTOR or RAS/RAF/MEK pathways, and 
targets currently in clinical investigation include poly(ADP-ribose) polymerases (PARP), 
PI3K and MEK, heat shock protein 90 alpha family class A member 1 (HSP90AA1), and 
histone deacetylase and androgen receptor inhibitors[5]. However, no driver alteration 
or genetic dependency has shown clinical benefits so far[5]. 
There are several factors to contemplate when designing a therapeutic strategy and, 
since the goal is to develop a viable clinical approach, it is important to consider its 
translation potential. Our strategy relied on downregulation of previously uncovered 
hits using small-hairpin RNA (shRNA). These activate RNAi machinery on the target cells 
and lead to the knockdown of the target gene[6]. While several options have proven 
effective in vitro, such as antisense oligonucleotides[7,8], the clinical translation of these 
approaches has proven challenging[9]. The use of small molecule inhibitors, on the 
other hand, can achieve high efficacy without major toxicity[9]. Nevertheless, 
posttranscriptional regulation of gene expression is prone to adaptation to new 
molecular targets arising from basic cancer studies and abolishes total protein function, 
which can be a limitation with small molecule inhibitors[10,11]. Still, efficacious 
strategies for gene delivery are needed for the full realization of RNAi potential to treat 
cancer. 
Viral vectors are increasingly used as gene delivery agents as they achieve high infection 
rates in vivo and their tropism can be engineered to target a receptor or cell of interest. 
The specific properties of Adeno-associated Viral (AAV) vectors make them attractive 
vectors to conduct in vivo gene therapy. These are engineered from adeno-associated 
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virus which are nonpathogenic, naturally replication-deficient and mostly non-
integrative, which greatly reduces their oncogenic potential[12]. Although gene 
replacement strategies have yielded promising results for inherited monogenic 
disorders, rAAV gene therapy now includes strategies for gene knockdown and gene 
editing[13]. rAAV vectors have been reported to transduce a wide variety of primary 
cancer cells and cell lines, and shown positive results as anticancer therapy delivery 
agents[14]. Moreover, the use of rAAV as a delivery platform for shRNA has been 
successful in preclinical and clinical trials for hepatitis C virus infection and chronic 
hepatitis B, α1-antitrypsin deficiency, facioscapulohumeralmuscular dystrophy, age-
related macular degeneration and retinitis pigmentosa and neurodegenerative 
disorders such as Huntington’s or Parkinson’s disease[15], further highlighting the 
potential for clinical translation of the developed therapeutic approach. 
Therefore, we implemented a platform for production and purification of rAAV vectors 
expressing shRNA sequences targeting the genes of interest. Production was based on 
transient transfection of HEK293 producer cells. Production platforms based on 
transient transfection can supply clinical trials that require limited vector doses, such as 
targeting the retina or brain, or that require small subset of patients, such as rare 
diseases[16]. Commercial options for establishing E.coli and HEK293 master cell banks, 
as well as for plasmid DNA and transfection reagents’ production are available, all 
qualified for preclinical and clinical testing, making this approach easy and fast to 
implement[16]. Alternatives with higher scalability include baculovirus, adenovirus and 
herpes virus production systems. These do, however, require more extensive lead time 
for master cell bank preparation and production vector preparation[16]. The final 
outcome includes larger vector lots, with doses reaching larger target organs and 
patient populations[16]. However, once this lead time has passed, the subsequent 
production of large scale lots is much faster than transient transfection[16]. Thus, at this 
stage in vector development, production platforms based on transient transfection 




One of the challenges in viral vectors encoding shRNA is the activation of the RNAi 
machinery on the producer cells[17]. This can take a toll on producer cell viability, likely 
impairing rAAV production. By changing the stoichiometry of the plasmids at 
transfection and decreasing the proportion of capsid-encoding plasmid on the 
transfection mix, the production of capsid proteins could be reduced and, consequently, 
reduce the number of empty capsids in the final preparation. Moreover, decreasing 
harvesting time to 48h further contributed to decrease the ratio of empty/full capsids, 
as producer cells presented higher viability at that time point. This strategy enabled the 
production of high quality rAAV batches, reaching yields comparable to current rAAV 
production platforms[16,18]. 
We validated the knockdown efficiency in BLBC cell lines in vitro and assessed each 
vector´s potential for BLBC treatment. While all vectors led to a reduction in overall cell 
viability, PSMA2 emerged as the most promising target since it induced specific 
apoptotic induction in vitro of up to 2-fold in a BLBC cell line. As the phenotype of cell 
lines can change when cultured in the 3D configuration, especially in the proliferative 
status, evaluation of its biological effect on a BLBC xenograft models was conducted. 
rAAV-mediated delivery of an shRNA targeting PSMA2 led to a persistent decrease in 
tumor progression over time. On the other hand, administration of rAAV-PLK1sh vectors 
showed an impact on tumor progression only at the highest dose tested. Interestingly, 
this was the only vector, other than rAAV-PSMA2sh, which resulted in a significant 
induction of apoptosis in vitro. However, PLK1 knockdown efficiency was lower, which 
could possibly account for the lower efficacy also observed in vivo. It is important to 
note that the lower efficacy of the rAAV2-PLK1sh was not due to a lower infection 
capability, as all developed rAAV vectors displayed comparable transduction efficiency 
in the cell lines tested. We cannot exclude the possibility that the tropism, and 
consequently the infection rate, could be altered in the mouse xenograft model, when 
compared to the transduction rates observed in vitro. However, since the rAAV capsid 
was maintained within all vectors tested, this effect would be visible in all vectors and, 
therefore, comparative analysis is still possible. Nevertheless, it is still an important 
limitation of the present study that we have not been able to identify gene target 
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knockdown in the analyzed tumors, nor detect eGFP expression. We hypothesize that 
the apoptosis induction in infected cells could be impairing the detection of eGFP 
expression and gene knockdown at the time points analyzed. Another interesting aspect 
is that rAAV2-PSMA2sh appears to lose its therapeutic effect at later time points. 
Although it is important to note that by that time point fewer replicates were tested, 
which decreases statistical power, it is still intriguing. This may reflect the tumor´s 
evolution along therapy and loss of therapeutic sensibility. In fact, several mechanisms 
have been linked to resistance to proteasome inhibition, namely overexpression of 
other proteasomal subunits, activation of the aggresome-autophagy pathway, heat 
shock protein and growth factor induction, among others[19]. 
Although gene therapy approaches based on AAV vectors have shown a very safe and 
efficacious profile in clinical studies, with no major toxicity events reported[20], its 
inherent biology poses important limitations for gene therapy applications, especially 
for cancer targeting approaches. In contrast to other frequently used viral vectors, such 
as retro and lentivirus, rAAV vectors are non-integrative, remaining mostly episomal 
after gene transfer[21]. While this decreases the risk for insertional mutagenesis, it also 
decreases the long-term efficacy when targeting proliferative tissues[12]. Therefore, 
another important limitation of the present study is the fact that multiple doses of rAAV 
injections were provided over the course of the treatment. Since AAV are ubiquitous 
and non-pathogenic, the majority of the human population has already come into 
contact with these viruses and, therefore, has preexisting immunity for the developed 
vectors[22]. Therefore, the goal has been to achieve a single dose approach, able to 
provide long-term transgene expression and therapeutic effect, as the neutralizing 
antibodies developed after the first injection would render further treatments 
ineffective[22]. 
Several strategies have been developed in an attempt to overcome these limitations. 
rAAV engineering for modification of its natural properties and acquisition of 
characteristics beneficial for gene therapy, such as decreased immunogenicity and 
increased infection efficiency, are an intense area of research. In the present work, 
AAV’s amenability for capsid engineering was exploited towards the development of 
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rAAV variants with increased tropism towards BLBC. In Chapter III, we used directed 
evolution approaches to restrict AAV2 tropism and uncover novel biomarkers for this 
important medical need. To date, the BLBC subtype is still characterized as a group of 
heterogeneous diseases that have in common the low or lack of expression of the typical 
BC biomarkers – ER, PR, Her2. Several attempts were made to try to subdivide this BC 
subtype into clinically useful categories. Nevertheless, these are still treated as a single 
entity with the same treatment option – cytotoxic chemotherapy. A vector with 
restricted tropism would give an additional safety level to the developed gene silencing 
strategy, adding to the previously established selectivity of the molecular targets, and 
ensuring that the therapy does not promote unspecific toxicity to normal cells and 
tissues. Furthermore, by restricting rAAV´s tropism to the tissue of interest, the therapy 
could be administered systemically, and possibly target BLBC in the metastatic setting. 
Since there are no biomarkers for this disease, a rational engineering approach was not 
possible. Therefore, after an initial depletion step using non-cancerous breast primary 
cells, sequential rounds of infection using several BLBC cell lines were performed. 
Unfortunately, a single capsid variant was selected. Upon analysis of its tropism, we 
were able to demonstrate higher transduction capacity towards BLBC cell lines. 
However, transduction efficiency was also increased for primary cells derived from 
mammary tissues, rendering the capsid variant ineffective for BC targeting approaches. 
Alternative routes for directed evolution include performing the screening for relevant 
variants using more accurate preclinical models, such as or 3D cellular models or animal 
systems[23,24]. Due to the lack of time these strategies were not followed within the 
scope of the present thesis but will be pursued in other projects in the Lab. 
1.2 Approaches for the development of 3D cellular models incorporating 
cues from the TME 
The potential of immunotherapies for the treatment of cancer has been shown in the 
success of checkpoint blockade therapies and adoptive T cell transfer 
approaches[25,26]. These can mediate complete tumor regression in a subset of 
patients. However, not all patients respond to the treatment. One of the working 
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hypotheses emphasizes the role of the TME surrounding the lesion, which can result in 
the inefficacy of immunotherapy in most cases. Different strategies are emerging to 
tackle the immunosuppressive nature of the TME and more accurate preclinical models 
are needed for accurate evaluation of those[3]. 
Based on an in vitro cellular model system developed in the Lab by Estrada et al.[27], 
we constructed a tumor model that incorporated key components found in the tumor 
microenvironment (TME). This model supported crosstalk between the different 
components through direct cell-cell contact and through the exchange of soluble 
factors. 
In the work developed within the scope of this thesis, NSCLC tumor spheroids, cancer 
associated fibroblasts (CAF) and monocytes were co-culture within alginate 
microcapsules and maintained for long-term in stirred culture systems.  
Within the tumoral compartment, H157 spheroids were composed of proliferative cells, 
positive for markers typical of aggressive stages of NSCLC, such as vimentin and N-
cadherin. Upon co-culture with CAF and monocytes, extensive accumulation of 
extracellular matrix (ECM) components, namely collagen types I and IV, and fibronectin, 
within the alginate microcapsules was observed. These allowed migration of the cellular 
components present[28], which enable an extensive spatial remodeling observed along 
culture time. Furthermore, the cytokine secretory profile of these cultures pointed to 
the development of an immunosuppressive environment, also reported in the TME of 
NSCLC patients[29]. It is important to note that there was no addition of exogenous 
differentiating factors; thus, observed cell phenotypes were a result of spontaneous 
interactions between the different cellular components. 
Upon three weeks of culture, the presence of CD68+ cells – macrophage marker - could 
be detected across the alginate microcapsules, indicating that the cultured monocytes 
were differentiated into macrophages. Both macrophages differentiated from THP1 and 
peripheral blood derived monocytes (PBM) expressed markers associated with M2-like 
pro-tumoral effects, namely CD163. Macrophages derived from PBM were also positive 
for the Mannose receptor C-Type 1 (MRC1, also known as CD206) marker, another 
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marker of M2-like macrophages[31]. These receptors have also been reported in tumor 
associated macrophages (TAM) present in several solid tumors, including NSCLC[30]. 
CD68+CD163+ TAM were correlated with poor progression-free survival and overall 
survival in NSCLC[32] and their presence was an independent prognostic marker for 
response to EGFR inhibitors[32]. By recapitulating this phenotype in vitro, this model 
could be used to identify key mechanisms inducing TAM differentiation and uncover 
new therapeutic strategies[33]. Also, identification of key modulators responsible for 
the differential response to treatment could help select patients that would benefit 
from combination therapies. 
Extensive infiltration of CD163+ macrophages into the tumor spheroids was observed 
in the triple co-culture, reminiscent of the myeloid infiltration in human NSCLC 
tumors[34]. This infiltration is crucial for the development of an accurate cellular model 
incorporating the TME since direct co-culture has been shown to promote M2-like 
activation states with induction of secretion of pro-tumoral factors such as EGF, and 
IL10[33]. Furthermore, the soluble factors detected in our model indicated the 
generation of an immunosuppressive TME, further contributing to M2-like polarization. 
In fact, even monoculture of NSCLC spheroids in alginate microcapsules had detectable 
levels of secreted IL4, IL10, IL13 and CXCL1, which increased in the triple co-cultures. 
IL10, IL4, and IL13 have been described to induce an M2-like polarization state in 
macrophages[34]. CXCL1, detected in our triple co-cultures, has been reported to be 
present in high levels at the TME of NCSLC and correlated with lower disease-free 
progression times; it has also been proposed as an indicator of NSCLC progression, 
together with other markers[35].  
To assess our cellular model´s amenability for drug testing, the effects of two standard-
of-care chemotherapeutic drugs – paclitaxel and cisplatin – were tested. Challenging 
our model with both cisplatin and paclitaxel led to apoptosis induction in the tumoral 
compartment. However, while the phenotype of NSCLC spheroids was not altered upon 
co-culture with CAF and TAM, the interaction with these cells did alter their sensitivity 
to the drugs. NSCLC spheroids presented reduced susceptibility to paclitaxel challenge 
when in triple co-culture, indicating that interaction with TAM and CAF in culture may 
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be inducing therapeutic resistance. We hypothesize that this could be a result of the 
higher cytotoxic effect that cisplatin demonstrated towards CAF-macrophage co-
cultures. This co-culture control presented pronounced reduction of viability upon 
cisplatin challenge when compared to monoculture of tumor spheroids and the triple 
co-culture, which may have limited their influence on the tumor compartment´s drug 
response. In fact, co-culture with macrophages has already been shown to mediate 
breast cancer cell resistance to paclitaxel, as well as other chemotherapeutics[36]. 
Furthermore, previous reports indicate that IGF produced by stromal cells promote 
cancer cell survival and resistance to therapy in pancreatic and brain tumors[37,38], and 
blockage of these growth factors was shown to increase the efficacy of paclitaxel 
therapy in metastatic breast cancer[39]. Lastly, CXCL1, which was detected at high levels 
in the triple co-cultures, mediates myeloid infiltration in breast cancer, which produce 
chemokines, such as S100A8/9, that enhance cancer cell survival[40]. Blocking CXCL1 
receptor – CXCR2 – increased the efficacy of chemotherapeutic drugs, including 
paclitaxel[40]. While additional studies should be conducted to further dissect the 
stroma-TME axis leading to decreased susceptibility to paclitaxel in the present model, 
these results indicate that previously described interactions between the different 
components are being recapitulated in the model, highlighting its potential to test 
combination approaches and uncover additional targets for combination therapy. 
Response to cisplatin, on the other hand, was maintained upon co-culture with CAF and 
TAM. An increased gene expression of CCR7 after cisplatin challenge was observed, 
suggesting that there was a shift in the macrophage surviving population towards an 
M1-like phenotype. No increased cytotoxic effect in tumor was observed as a 
consequence of repolarization. Nevertheless, repolarization of macrophages and its 
effect on tumor cells may be dependent on T cell activation, which is absent in our 
model[41]. On the other hand, activation of CCR7 signaling was shown to promote 
survival of cancer cells after EGFR and cisplatin treatments in head and neck squamous 
carcinoma[42]. Since CCR7 signaling has also been linked to proliferation and decreased 
apoptosis in NSCLC[43], the increased expression of CCR7 after cisplatin treatment may 
reflect the decreased sensitivity of these cells to the therapy and consequent increased 
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proportion in culture. To assess these effects, the expression of CCR7 should be 
evaluated in FACS-isolated tumor and macrophages, separately. 
The plasticity and high response to stimuli characteristic of TAM was also supported in 
the developed model, as evidenced by immunomodulation upon culture exposure to a 
CSF1R inhibitor, BLZ945. Several clinical studies are ongoing to investigate the effect of 
targeting TAM using CSF1R inhibitors[41]. CSF1R inhibition resulted in altered TAM 
recruitment and repolarization of the macrophages within TME into a pro-tumoral M1-
like state, which was shown to contribute to tumor regression in mouse models of brain 
and breast cancer[44–47]. Upon challenge, the macrophage population expressing M2-
like markers decreased, in parallel with an increase of the gene expression of M1-like 
receptor CCR7. This suggests that the repolarization effect already described for CSF1R 
inhibition was reproduced in culture. Moreover, there was no decrease in viability 
observed upon BLZ945 challenge, indicating that the lower proportion of M2-like 
macrophages in culture was not a result of cell death. Also, gene expression analysis of 
macrophage marker CD68 showed that it was maintained along drug treatment, further 
supporting this hypothesis. 
Although their translation into clinical trials has shown manageable safety profiles, the 
use of CSF1R inhibitors as monotherapy has led to disappointing results in solid 
tumors[48]. The most advanced CSF1R inhibitor in clinical development has showed 
limited efficacy in glioblastoma patients and no objective responses[48,49]. The 
attrition rates observed in ongoing clinical trials may reflect intrinsic differences 
between murine and human responses to CSF1R blocking. The model system here 
developed could be used to identify factors that are limiting the effect of CSF1R in 
humans, and to test in a human setting the combinations of CSF1R inhibition with 
immuno-, chemo- and targeted therapies, currently ongoing[48].  
Although few blockers of Th2 cytokines, such as IL4 and IL13, have gone through clinical 
trials for solid tumors, recent reports suggest that blocking of this crosstalk may be 
favorable for combination with radiotherapy or paclitaxel-chemotherapy in slowing 
tumor growth in mammary tumors[50]. In this setting, therapeutic effects were CD8+ T 
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cell dependent, thus incorporation of T cells in the developed model should be 
evaluated. Nevertheless, the strong accumulation of these cytokines in culture may 
merit its use for dissection of the effects of cytokine-targeted therapies. 
The pro-tumoral effects of TAM can be mediated by their interaction with other cells. 
Hence, markers for additional cell populations should be investigated to fully evaluate 
the potential of the model developed. Monocytic precursors can also give rise to other 
cells contributing to the immunological state of the TME, such as MSDC and dendritic 
cells[33]. Clinical significance of these cells has been extensively explored in terms of 
their effect on tumor progression and response to drugs[51,52]. Thus, their presence 
and influence within this model should be investigated. 
Moreover, several of the effects of TAM discussed previously are mediated through the 
activation of T cells. Additionally, TAM can directly suppress T cells through the 
expression of inhibitory receptors, and the cooperation effect of CSF1R inhibition and 
checkpoint inhibitors or adoptive T cell therapy has been shown[53–56]. Hence, given 
their overrepresentation in current immunotherapeutic targets, the inclusion of T cells 
in in vitro models should be explored. Using patient-derived tumor samples in 
combination with peripheral blood-derived mononuclear cells from the same donor 
could open these possibilities. Finally, the broad application of the developed platform 
to other pathologies and patient-derived tumour samples could give clinicians an 
opportunity to perform ex vivo assessment of therapeutic efficacy using precision 
medicine approaches.  
2. FINAL REMARKS 
The advances in pharmacogenomics over the recent years aim at providing a rational 
stratification of patients for a given therapy[57]. This could revolutionize precision 
medicine by uncovering the most relevant genetic drivers and cellular pathways 
mediating disease progression and therapeutic response in a genetically defined subset 
of patients[57]. However, the development of therapies for a given tumor indication 
has proven an often inaccurate and complex process, as have therapeutic biomarker 
identification, which is often a slow and inefficient[58]. Following in vitro observation of 
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a given mechanism or pathway, standard animal testing follows, using mostly mouse 
models[59]. Since the majority of these models presents compromised immune systems 
and offers non-human tumor-stromal interactions, the concurrence rate of clinical 
translation can be as low as 8%. Moreover, the pain and discomfort these animal 
undergo are a growing concern[60,61]. Thus, the development of accurate in vitro 
cellular models aims at bridging the gap between traditional in vitro and in vivo models. 
By providing tumor phenotypes that better resemble the in vivo setting, and by 
eliminating the interspecies discrepancies of cellular interactions in in vivo models, 
these could allow more accurate disease modeling and drug testing. The development 
and applications of strategies that could target specifically the cell of interest, within 
such heterogeneous environments, would facilitate the process and generate safer 
therapies, with fewer side-effects. 
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